Uncategorized

Cannabis: a multifaceted plant with endless potentials

By June 16, 2023July 4th, 2023No Comments
 2023; 14: 1200269.
Published online 2023 Jun 15. doi: 10.3389/fphar.2023.1200269
PMCID: PMC10308385
PMID: 37397476

Abstract

Cannabis sativa, also known as “hemp” or “weed,” is a versatile plant with various uses in medicine, agriculture, food, and cosmetics. This review attempts to evaluate the available literature on the ecology, chemical composition, phytochemistry, pharmacology, traditional uses, industrial uses, and toxicology of Cannabis sativa. So far, 566 chemical compounds have been isolated from Cannabis, including 125 cannabinoids and 198 non-cannabinoids. The psychoactive and physiologically active part of the plant is a cannabinoid, mostly found in the flowers, but also present in smaller amounts in the leaves, stems, and seeds. Of all phytochemicals, terpenes form the largest composition in the plant. Pharmacological evidence reveals that the plants contain cannabinoids which exhibit potential as antioxidants, antibacterial agents, anticancer agents, and anti-inflammatory agents. Furthermore, the compounds in the plants have reported applications in the food and cosmetic industries. Significantly, Cannabis cultivation has a minimal negative impact on the environment in terms of cultivation. Most of the studies focused on the chemical make-up, phytochemistry, and pharmacological effects, but not much is known about the toxic effects. Overall, the Cannabis plant has enormous potential for biological and industrial uses, as well as traditional and other medicinal uses. However, further research is necessary to fully understand and explore the uses and beneficial properties of Cannabis sativa.

Keywords: marijuana, cannabiniods, pharmacology, ethnobotany, phytochemistry

1 Introduction

Throughout human civilization, there has been a pursuit of plants for their unique potential, including medicinal use. Evidence of this dates back to 60,000 years, with a recent discovery of a 5,000-year-old Sumerian clay tablet that confirms the use of medicinal plants in drug production (). Natural resources like medicinal plants, also known as green medicine, are gaining popularity worldwide due to their safety, effectiveness, cultural acceptance, and lower risk of adverse effects compared to synthetic medications (). Today, traditional botanical medicines are widely used to treat human health problems, with over 80% of the global population depending on them ().

Cannabis sativa L. (2n ¼ 20) is a well-known plant that has been around since the beginning of time (). This annual plant is a member of the family Cannabaceae and a widespread plant found in varied environments (). It has been used by humans for over 5,000 years and is one of the oldest plant sources of food and fiber (). The botanical types of Cannabis sativa differ in terms of their chemical content, plant growth habits, agronomic requirements, and processing (). Cannabis flowers and leaves have a distinctive aroma, and the plant’s extracts include a variety of beneficial flavonoids, terpenes, and other compounds that are efficient insecticides, fungicides, and therapeutic agents (). The flower, leaves, oil, and trichome of the plant have been shown to be cytotoxic, antimicrobial, antioxidant, antihypertensive, antipyretic, and appetite-stimulating (). The flower extracts with antioxidant activity have been shown to have health-promoting and anti-aging properties, and are utilized to treat a variety of metabolic and chronic disorders, including glaucoma, pain, depression, cancer, liver disease, cardiovascular diseases, inflammation, and metabolic syndrome (). As an agricultural crop, industrial Cannabis (hemp), is a plant that may be harvested for its fiber (). While in the cosmetic industry, it is used for skincare products such as anti-aging creams and hair food (). Traditionally, the seeds are used for making oil, while the leaves were the second most consumed part of the plant and were used in various ways, such as seasoning, baking, flour, and added to meals ().

Even though Cannabis is used in many ways, the drug’s unclear legal status worldwide has made it hard to study for the last century (). In addition, there has not been much information about comprehensive analysis of the plant that can show the plant’s usefulness in all aspects. In this review, Cannabis’ potential is discussed in length to provide thorough and up-to-date information on the Cannabis plants.

2 Ethnobotany of Cannabis

2.1 Ecology and distribution

Cannabis sativa’s origin is unknown, but it is believed to have come from temperate regions in Asia, specifically the southern Caspian region, Siberia, China, or the Himalayas (). However, due to widespread transportation and modification by humans over the past 6,000 years, it is challenging to determine its original geographic range or whether a plant collected in nature is a primitive wild type or has been influenced by human domestication (). “Weed” is the most common informal name for the marijuana form of Cannabis sativa, and it accurately describes the species as a weed that grows primarily in habitats created or modified by humans (). It can be found in various places such as fields, trash heaps, vacant lots, pastures, ditches, creeks, and open woods. However, it is poorly adapted to infiltrating established perennial stands and typically invades only after the soil has been recently disturbed or plowed ().

Except in drainage channels, where it is extremely well suited, weedy Cannabis sativa is a slow colonizer, spreading slowly throughout the landscape. It is possible to judge the ecology of Cannabis sativa prior to human intervention based on the circumstances and adaptations of existing wild-growing populations of this plant species (). By examining the circumstances and adaptations of these populations, researchers can gain insight into the plant’s natural habitat, growth patterns, and environmental interactions. For example, studying the genetic diversity of wild-growing Cannabis sativa populations can provide information on the plant’s evolutionary history and geographic distribution (). Additionally, analyzing the physical characteristics of wild Cannabis sativa plants, such as their size, leaf shape, and stem structure, can provide clues about their adaptation to various environmental conditions ().

2.2 Taxonomic classification and common names

Before Linnaeus published Species Plantarum in the 18th century, domestic hemp was known by various names, including Cannabis angustifoliaCannabis sativa, and Cannabis indica (). Later, Jean-Baptiste Lamarck proposed a division between extensively cultivated Cannabis species in western continents and the wild variety found in India (). After 50 years, Lindley reclassified Cannabis under Linnaeus’ classification system, affirming the plant’s monospecific status for the rest of the century (). Below is the botanical classification of Cannabis plant (Figure 1) (). In the early 20th century, a new species called Cannabis ruderalis emerged, but it was not until 1975 that the restoration of the Cannabis indica species to its current name was proposed (). Figure 2 presents the name of Cannabis in some popular languages.

An external file that holds a picture, illustration, etc. Object name is fphar-14-1200269-g001.jpg

Taxonomic classification of Cannabis plant.

An external file that holds a picture, illustration, etc. Object name is fphar-14-1200269-g002.jpg

The name of Cannabis in some popular languages.

Cannabis is a polymorphic plant, and chemotaxonomic markers are effective in differentiating between different Cannabis germplasms and screening for hybrids ().  used biphasic techniques (use of distinct approaches) to identify the four subspecies of Cannabis sativa, including sativa var. sativasativa var. spontaneaindica var. indica, and indica var. kafiristanica based on morphological and chemical characteristics such as fruit morphology and THC content (). Both variants of the subspecies sativa are widely cultivated in North America, Europe, and Asia, and have low intoxicating potential when compared to other Cannabis cultivars (). Meanwhile, the subspecies Indica’s variants have a strong intoxicating potential and are primarily found in the Asiatic Continent ().

2.3 Legality-based classification

Despite being an arbitrary term that does not reflect the drug’s properties, Cannabis is classified as a “narcotic” (i.e., illegal drug) in the legal world (). An illegal drug is defined as a chemical or preparation associated with severe punishments due to its actual or suspected detrimental properties (). Cannabis has been criminalized since the Second World War due to its popular use as a recreational substance, leading to limited research and commercial development in the sector. As a result, research and commercial development on the plant was prohibited for most of the 20th century (). Cannabis sativa became the most commonly cultivated black market crop in the Western world after World War II, leading to the allocation of significant law enforcement resources to remove the plants (). Scientific investigations in Western countries were mostly approved for criminal justice-related forensic studies to assist law enforcement or medical and social-related studies to document and alleviate negative consequences ().

Criminalizing Cannabis has led to high law enforcement costs and social instability, and many jurisdictions are looking to reduce penalties for its possession and consumption (). The legalization of medical Cannabis is widely accepted, but recreational use is still under debate (). While punishments for illegal drug use have softened in several countries due to increased public acceptance, although, capital punishment is still a possibility in some Asian countries (). The decriminalization of Cannabis use is not unique to the North American continent. More than forty countries have legalized the use of marijuana for medical or recreational purposes. Among these countries are Argentina, Germany, Chile, Colombia, and South Africa (). Additionally, Canada, 18 United States states, and two territories—the District of Columbia and the Australian Capital Territory—have legalized Cannabis. New strains are approved for use in Canada until 2023, and Health Canada has issued regulations amending the Cannabis Act and Cannabis Regulations to ensure proper regulation of Cannabis ().

2.4 Therapeutic based classification

The cannabinoids in Cannabis are unique terpene phenolic substances. Approximately 100 cannabinoids are produced in epidermal trichomes but in small quantities (). As discussed by Cannabis’ psychological effects have been ambiguously called “narcotic” in popular, legal, and scientific contexts. Cannabis and opioids are legally grouped, but they are pharmacologically distinct. “Narcotic” comes from “narcosis,” a substance that induces sleep, but it is used to refer to any medicine that induces sleep, stupor, or insensibility (). In moderate amounts, psychoactive cannabinoids such as THC and CBD in Cannabis can induce sedation (). CBD has a stimulant effect in low and moderate concentrations, and only in high concentrations has a soothing effect (). Cannabis sativa’s abundant myrcene is likewise sedative (). There is still some disagreement on how Cannabis should be pharmacologically classified (). In some cases, Cannabis has been classified as a sedative-hypnotic-general anesthetic, a mixed stimulant-depressant, a mild hallucinogen, and a psychedelic (). In surgical and dental procedures, it is referred to as a sedative-hypnotic general anesthetic. Cannabis’s psychedelic, hallucinogenic, psychotomimetic, and psychotic properties are misrepresented by terms like “psychedelic” (). While “hallucinogenic” is no longer acceptable, “psychoactive,” “euphoric,” or “intoxicating” are the best pharmacological names for Cannabis (). According to , medical Cannabis users in the United States are characterized by daily dosing and weekly consumption of 6–9 g (). In Canada, 42% of medical marijuana patients consume 2 to 3 times a day, and 40% consume more than 14 g per week. In Canada and the United States, most patients inhale (). Surprisingly, only 53% of adult Cannabis users in the United States use Cannabis purely for recreational purposes, while 47% use it “in part or totally for medicinal purposes,” and 10% use it solely for medicinal purposes (). Research shows that in 2004, about 4% of Canadians over the age of 14 reported using Cannabis in the past year for self-identified medical problems (). Cannabis remains the most commonly used drug globally, with more than 4% of the global population aged 15–64 (approximately 209 million people) using Cannabis in 2020, a 23% increase from 170 million in 2010 (). Approximately 27% of Israeli adults consumed Cannabis in 2020, making it the country with the highest incidence of Cannabis use as of that year. (). Comparatively, the United States has a lower incidence of Cannabis use, with approximately 17% of the adult population reported to have consumed Cannabis within the same period (). In Europe, Czechia has the highest incidence of Cannabis use of 11.1% among their adult population (). Forecasts put the global Cannabis market at $82.3 billion in 2027, a significant projection of 24.3% with $27.7 billion recorded in 2022 (). The United Nations Office on Drugs and Crime (UNODC) identifies Morocco as the largest producer of ‘psychoactive marijuana plants’ worldwide (). However, in terms of revenue generation, the United States leads in terms of the sale of medical Cannabis, with an annual total of 10 billion dollars, a significant portion of which comes from therapeutic marijuana (). In Europe, Germany leads in the sale of medical marijuana, with an estimate 87.2 million dollars (). Between 1995 and 2005, 19 African countries reported the cultivation of Cannabis within their borders. In 2005, worldwide, Cannabis production was estimated at 42,000 metric tons, with Africa alone accounting for 25% of the total ().

2.5 Morphological characteristics of Cannabis

Cannabis sativa L. is an annual plant that can reach up to 5 m in height and has upright stems with palmate leaves consisting of 5–7 linear-lanceolate leaflets (Figure 3). Male flowers lack petals and grow in axillary or terminal panicles, while female flowers have a single ovule and a perianth that is tightly attached (). Trichomes, which are glandular protuberances that cover the plant’s leaves, bracts, and stems, are present in high concentrations (). The fruit of each flower is a single small smooth light brownish-grey fruit that is then passed on to the next-generation. Female flowers grow at the end of the stem and in the axils. They have one ovule and a perianth that is tightly connected. Male flowers, on the other hand, have five yellowish petals and five anthers ().

An external file that holds a picture, illustration, etc. Object name is fphar-14-1200269-g003.jpg

Parts of Cannabis plants and products.

3 Phytochemistry of Cannabis

The number of natural chemicals isolated from Cannabis sativa L. has not significantly increased in recent years, despite over 500 compounds being discovered so far (). In 1980, 423 compounds were discovered, which grew to 483 by 1995 (). Currently, 566 compounds have been identified and isolated which constitutes over 18 classes of different secondary metabolites found in the plant. These substances have been found to be highly abundant in the flowers and leaves of the plant (). Out of this number, 125 are cannabinoids, 198 are non-cannabinoids and 120 are terpenes, constituting a total of 443. The rest of the substances identified in the plant in 2021 include 2 alkaloids, 34 flavonoids, 42 phenols and 3 sterols (). The aromatic quality of female Cannabis plants is due to the terpenes they produce, such as pinene, limonene, terpineol, and borneol (). These terpenes have insect-repellent properties and inhibit the growth of neighboring vegetation. The glandular trichomes on the plant produce a resin that acts as a sophisticated defense mechanism against insects and has the potential to serve as an antibiotic and antifungal agent. These trichomes contain secondary metabolites like phytocannabinoids and terpenoids that are responsible for the plant’s defense and interaction with herbivores and pests, as well as its characteristic scent (). The various phytochemicals are summarized below.

3.1 Cannabinoids

Therapeutic marijuana has a high level of tetrahydrocannabinol (THC), but minimal levels of cannabidiolic acid (CBDA) and cannabidiol (CBD). Cannabinoids undergo decarboxylation during drying, storage, and thermal processing, converting from an acidic to a neutral state. There are now many types of cannabinoids, not just those found in Cannabis, and the term “phytocannabinoids” has been used for those that naturally come from the plant (). A total of 120 phytocannabinoids have been identified and divided into 11 categories (). Table 1 lists the 11 subclasses of 120 phytocannabinoids.

TABLE 1

Phytocannabinoids discovered in Cannabis sativa L.

No. Cannabinoids Molecular structure Reference
1 (–) – Δ9-trans-tetrahydrocannabinol (Δ9-THC) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx1.jpg
2 (–)-Δ8trans-tetrahydrocannabinol (Δ8-THC) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx2.jpg
3 Cannabigerol (CBG) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx3.jpg
4 Cannabichromene (CBC) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx4.jpg
5 Cannabidiol (CBD) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx5.jpg
6 Cannabinodiol (CBND) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx6.jpg
7 Cannabielsoin (CBE) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx7.jpg
8 Cannabicyclol (CBL) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx8.jpg
9 Cannabinol (CBN) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx9.jpg
10 Cannabitriol (CBT) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx10.jpg
11 Miscellaneous types
i Dehydrocannabifuran (DCBF-C5) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx11.jpg
ii Cannabifuran (CBF-C5) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx12.jpg
iii Cannabichromanone (CBCN-C5) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx13.jpg
iv Bisnor-Cannabichromanone (CBCN-C3) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx14.jpg
v Cannabicoumaronone (CBCON-C5) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx15.jpg

 

3.1.1 (−)-Delta-9-trans-tetrahydrocannabinol (Δ9-THC) type

 discovered the structure of Δ9-THC and explained its psychoactive properties.  used X-ray and proton magnetic resonance (1H NMR) studies to determine the precise conformation of Δ9-THC ().  identified Δ9-THCA-A from Cannabis extract, which is photosensitive and cannot form crystals (structure as compound 2 shown in Table 1) ().  discovered Δ9-THCA-B (compound 3 in Table 1) from CannabisCannabis sole, a flat form of illicit Cannabis, was eluted from the silicic acid matrix using a 1:1 diethyl ether/petroleum ether solution. Δ9-THCA-B was shown to be more polar than Δ9-THCA-A in thin-layer chromatography (TLC). The determination of the crystalline structure of Δ9-THCA-B was due to the differences in biochemical properties between Δ9-THCA-B and Δ9-THCA-A ().

 isolated Δ9-tetrahydrocannabivarin (Δ9-THCV) using a mixture of 5 g of Cannabis and 200 mL of petroleum ether and dissolved it in 100 mL of absolute ethyl alcohol (EtOH) (). Spectroscopic evidence for Δ9-trans-tetrahydrocannabidiolic acid (Δ9-THCVA) was reported by , followed by mass spectrometric evidence data (). The analysis of 51 samples sourced from various geographic regions led to research on the C3 homologs of Cannabis ().  discovered a new homologue of Δ9-THC with a methyl side chain, 9-tetrahydrocannabiorcol (Δ9-THC-C1), in an extract of Brazilian Cannabis (). The concentration of Δ9-THC-C1 was low, so it was not expected to have a significant impact on the drug’s biological action.  identified Δ9-trans-THCA-C4 and Δ9-trans-THC-C4 using GC-MS, as well as Δ9-trans-tetrahydrocannabiorcolic acid (Δ9-THCA-C1) (). Several techniques, including NMR spectroscopy and Gas Chromatography-Mass Spectrometry (GC-MS), were used to identify monoterpene or sesquiterpene esters of 9-tetrahydrocannabinolic acid A in Cannabis sativa L. These esters were found to be precursors to Δ9-THC and were broken down into their constituents when subjected to high temperatures during GC-MS analysis (). Chromatographic methods, such as vacuum liquid chromatography (VLC), High-performance liquid chromatography (HPLC), and Supercritical fluid chromatography (SPC) were used to isolate these cannabinoid esters from high-potency C. sativa varieties. Cannabisol, a dimeric cannabinoid, was also isolated using flash silica gel column chromatography from Cannabis samples that contained a significant amount of CBG (). Eight new substances of the tetrahydrocannabinol family are listed in Table 2.

TABLE 2

Novel substances of the tetrahydrocannabinol class.

S/N Tetrahydrocannabinol Molecular structure Reference
1 β-Fenchyl-Δ9-tetrahydrocannabinolate An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx16.jpg
2 α-Fenchyl-Δ9-tetrahydrocannabinolate An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx17.jpg
3 epi-Bornyl-Δ9-tetrahydrocannabinolate An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx18.jpg
4 Bornyl-Δ9-tetrahydrocannabinolate An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx19.jpg
5 α-Terpenyl-Δ9-tetrahydrocannabinolate An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx20.jpg
6 4-Terpenyl-Δ9-tetrahydrocannabinolate An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx21.jpg
7 α-Cadinyl-Δ9-tetrahydrocannabinolate An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx22.jpg
8 γ-Eudesmyl-Δ9-tetrahydrocannabinolate An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx23.jpg

 

3.1.2 Cannabigerol (CBG) type

Cannabigerol (CBG) is the first substance purified from Cannabis resin (CBG-C5, compound 5 in Table 1) ().  were the first to describe the condensation of geranyl pyrophosphate in the formation of CBG.  discovered that cannabidiolic acid (CBGA) was the most polar acid component. They also found the methyl ester of CBGA in the acidic part of a single extract of Cannabis ().

Cannabigerovarinic acid (CBGVA–the structure of compound 1 in Table 3) isolated from an extract of the dried leaves of Thai Cannabis was found to be a minor component of the extract (). After extraction of the acid fraction from the leaves using silica gel column chromatography, the acid fraction was eluted from the dried leaves using a mixture of hexane, ethyl acetate, and a ratio of 5:1 of benzene to acetone. The transparent needle-like CBGVA crystals were obtained following recrystallization in hexane: ethyl acetate solution in a ratio of 3:1.

TABLE 3

Summary of some isolated cannabinoids.

No Cannabinoids Molecular structure Part of plant Extraction solvent References
1 Cannabigerovarinic acid (CBGVA) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx24.jpg leaves Benzene, acetone
2 γ-Eudesmyl cannabigerolate An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx25.jpg leaves hexane
3 α-Cadinyl cannabigerolate An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx26.jpg leaves hexane
4 Cannabichrome Varinic An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx27.jpg Young leaves acetone
5 (±)-4-Acetoxycannbichromene An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx28.jpg leaves hexane
6 (±)-3′′-Hydroxy- Δ4′′-cannabichromene An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx29.jpg leaves hexane
7 (±)-7-Hydroxycannbichromeme An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx30.jpg leaves hexane
8 Cannabinol (CBN) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx31.jpg Cannabis resin ethanol
9 Cannabimovone (CBM) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx32.jpg Hemp leaves hexane
10 Cannabivarin (CBN-C3) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx33.jpg Trichomes of flowers Chloroform and hexane
11 Cannabicyclol (CBL) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx34.jpg Dried leaves benzene
12 Cannabicyclolic acid (CBLA) An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx35.jpg Dried leaves benzene
13 Cannabicyclovarin An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx36.jpg Dried leaves benzene

Cannabinerolic acid (CBRA) and cannabigerolic acid (CBGA) are both acidic cannabinoids that are produced in the Cannabis plant. The primary difference between the two is the location of the double bond in their molecular structures (). CBGA is the precursor to many of the other cannabinoids found in Cannabis, including THC and CBD. It is synthesized by the plant from olivetolic acid and geranyl pyrophosphate. CBGA can be further converted into THCA, CBDA, or CBCA, which are then decarboxylated to produce THC, CBD, or CBC (cannabichromene) ().  described a procedure to purify cannabinerolic acid from an air-dried Mexican strain of C. sativa by extracting the leaves with benzene. The extraction was concentrated and loaded onto a silica gel column, then extracted with a 9:1 (v/v) benzene/acetone mixture after dissolving the residue in acetone and removing any insoluble particulates. High-potency cannabigerolic acid esters, i.e., γ-eudesmyl cannabigerolate and α-cadinyl cannabigerolate were also recovered from C. sativa in another study (). The hexane extract of Cannabis was purified by chromatography to obtain the two cannabigerolic acid esters. Both γ-eudesmyl cannabigerolate and α-cadinyl cannabigerolate were shown to be esters of CBGA by the data obtained from their respective spectroscopic analyses ().  identified six substances using flash silica gel analysis of a hexane extract, including 5-acetyl-4-hydroxycannabigerol, 4-acetoxy-2-geranyl-5-hydroxy-3-n-pentylphenol, (±)-6,7-trans-epoxycannabigerolic acid, (±)-6,7-cis-epoxycannabigerolic acid and (±)-6,7-cis-epoxycannabigerol ().  isolated a novel, polar dihydroxy cannabigerol derivative (carmagerol) from the Cannabis leaves.  identified sesquicannabigerol, a lipophilic analogue of cannabigerol, in the waxy section of the fiber hemp cultivar Carma. Methanolic potassium hydroxide (·KOH) was used to hydrolyze the wax, and it was purified using gravity silica gel column chromatography before being subjected to flash chromatography over neutral alumina ().

 

3.1.3 Cannabichromene (CBC) type

 reported the independent discovery of cannabichromene (CBC-C5), which is listed as compound 6 in Table 1. Later, CBC-C5 was isolated from dried the leaves at a yield of 1.5% using a method outlined by  and extracted cannabichromenic acid (CBCA) from the benzene percolate. The production of CBCA using a solvent system of 1:1 hexane and ethyl acetate was confirmed using NMR spectroscopy ().

The study found that cannabichromenic acid (CBCA) showed similarities to the structure of THCA in its infrared (IR) spectra due to the placement of the carboxyl group and the presence of intermolecular hydrogen bonding. The researchers isolated cannabichromevarin (CBCV), a brownish-red cannabinoid, from neutral cannabinoids obtained from Thai Cannabis leaves through multiple passes through a silica gel column and elution with benzene and 20:10:1 benzene-hexane (). Cannabichromevarinic acid (CBCVA), was isolated in young leaves of Cannabis, using acetone (). Synthesis was used to validate the structure of natural CBCVA.  reported the isolation of three new cannabichromene type cannabinoids from high-potency benzene extract of the flowers (trichomes). These cannabinoids are named (±)-4-acetoxycannabichromene, (±)-3″-hydroxy-Δ4″-cannabichromene and (±)-7-hydroxycannabichromeme ().

 

3.1.4 Cannabidiol (CBD) type

The two main metabolites of non-psychotropic (fiber-type) Cannabis cultivars are cannabidiol (CBD) and cannabidiolic acid (CBDA), their structures were shown in Table 1 as compounds 7 and 8, respectively. CBD was isolated, from the ethanol extract of leaves, and after being left for several weeks, the oily CBD was crystallized ().  reported its synthesis and absolute configuration as (−)-trans-1R, 6R. Cannabidavarin (CBDV) was isolated from an ethanol extract of Cannabis olein (flower), which was chromatographed on silica gel ().  extracted neutral cannabinoids from the ethanol extract of leaves to produce cannabidiol monomethyl ether (CBDM) (M-1). Benzene was used to elute the cannabinoids after they had been chromatographed on Florisil. To produce CBDM, the eluted fraction was rechromatographed on silica gel and eluted with a ratio of 3:1 hexane/benzene.

Cannabis resin and leaves that had been crushed were percolated with ethyl acetate to produce a residue that was filtered and concentrated. This residue was derivatized prior to GC-MS analysis. The mass and methylene unit of cannabidiol-C4 allowed for its identification ().  extracted cannabidiolic acid (CBDA) from the benzene extract of Thailand Cannabis. Cannabimovone (CBM) is a polar cannabinoid that was isolated from an acetone extract of Cannabis sativa L. leaves which is not psychoactive ().

 

3.1.5 Cannabidiol (CBND) type

The aromatized derivatives of CBD are called CBND-type cannabinoids (Figure 4). The two compounds in this subclass that are characterized are cannabidiol (CBND-C5) and cannabidiol (CBND-C3) (). By using a hexane-ether extract of Lebanese Cannabis (resinous trichomes),  were able to successfully isolate cannabidiol. GC-MS analysis revealed the presence of cannabidiol-C3, the propyl homolog of cannabidiol-C5 ().

An external file that holds a picture, illustration, etc. Object name is fphar-14-1200269-g004.jpg

CBND-type cannabinoids.

 

3.1.6 Cannabielsoin (CBE) type

The Cannabielsoin (CBE-C5), Cannabielsoic acid A (CBEA-C5 A), Cannabielsoic acid B (CBEA-C5 B), Cannabielsoin-C3 (CBE-C3), and Cannabielsoic-C3 acid B (CBEA-C3 B) are the five cannabielsoin-type cannabinoids present in Cannabis (). CBE was isolated from an ethanolic extract of hashish (resinous trichomes of flowers) originating in Lebanon (). CBEA-C5 A and CBEA-C5 B were extracted from a benzene extract of Cannabis (resinous trichomes) that was grown in Lebanon ().

 

3.1.7 Cannabicyclol (CBL) type

The only compounds that have been identified from this subclass are known as cannabicyclol (CBL), cannabicyclolic acid (CBLA), and cannabicyclovarin (CBL-C3) (Figure 5) ().  are credited with being the first to identify CBL. They used TLC to isolate CBL from a variety of benzene extract of dried leaves of Cannabis samples.

An external file that holds a picture, illustration, etc. Object name is fphar-14-1200269-g005.jpg

Types of cannabicyclols.

 

3.1.8 Cannabinol (CBN) type

Cannabinol (CBN) was given its name for the first time in 1896 (). CBN was made into oil by extracting Cannabis resin using ethanol and heating it. After some time, the oil was acetylated to get pure CBN in the form of its acetate.  were able to correctly estimate the structure of CBN. A crude acidic fraction of hashish was used to isolate cannabinolic acid A (CBNA), which was then esterified with diazomethane and purified as its methyl ester on an acid-washed alumina column (). Cannabivarin (CBN-C3) was extracted using a mixture of chloroform and hexane from Nepalese hashish (resin trichomes of flowers), and the structure of the compound was validated by mass spectrum data (). A summary of some isolated cannabinoids is presented in Table 3.

3.2 Other phytochemicals in Cannabis

 

3.2.1 Terpenes

Terpenes are aromatic compounds that are found in many plants, and they perform various biological roles, such as attracting pollinators and protecting against predation (). In the Cannabis plant, terpenes are stored as essential oils. Currently, over 200 distinct terpenes have been identified in Cannabis, with most of them being discovered through steam distillation ().

Terpene concentrations can vary due to various genetic factors. In Cannabis flowers, terpenoid concentrations were found to range from 1% up to 10% within the trichomes as of 2009. However, selective breeding has led to an increase in terpenoid concentrations found in flowers in recent years, with some chemovars exhibiting concentrations of 3.5% or higher (). Currently, over 50 different terpenes have been identified in Cannabis, with a few dominating compounds classified as the “terpene super class,” including linalool, ocimene, limonene, myrcene, α-pinene, humulene, β-caryophyllene, and terpinolene (). Similarly, Fischedick and others (2017) analyzed Cannabis samples and classified them into five distinct groups based on the above terpenoid classifications ().

Secondly, several terpenes found in Cannabis exist as hydrocarbons which are direct products of terpene synthase enzymes as compared to complex terpenes that require adjustments by other enzymes such as cytochrome P450 (). It can be concluded that the chemical diversity of terpenes in Cannabis is a direct reflection of the encoding enzymes in Cannabis. Other common terpenes in Cannabis are bisabolol, sesquiterpenes, and β-farnesene, (). Monoterpenes have a ten-carbon isoprenoid precursor known as the geranyl diphosphate (GPP), while sesquiterpenes have a fifteen-carbon isoprenoid farenesyl diphosphate (FPP) (). Therefore, in the synthesis of sesquiterpenes and monoterpenes, GPP and FPP act as substrates in producing different structures of terpenes.

 

3.2.2 Flavonoids

At least 20 flavonoids have been found in Cannabis, most of which are flavanols and flavones (). In 2011, three geranylated flavones known as cannflavin A, B, and C were found in the plant (). Currently, the leaves, flowers, seedlings, and fruits of C. sativa have been found to contain flavonoids that remain undetected in roots and seeds (). Apart from finding this compound in specific regions of the plant, flavonoids have been identified to vary in bracts during plant development ().

Since several flavonoids have protective functions, their production is dependent on environmental factors that have been found in several plants as well as Cannabis. For instance, the accumulation of cannflavin A is predisposed to genetic variations, as well as environmental factors such as temperature, rainfall, and humidity in the environment (). Besides, the contents of cannflavin A, B, and C in cloned species of C. sativa vary at different altitudes (). With these findings, it can be postulated that identifying unknown flavonoids in the plant, is reliant on certain environmental conditions or stresses. Another study by  confirms that certain flavonoids are produced in significant quantities in hexane extracts of flowers of C. sativa chemovars like cannflavcin C. Thus, identifying more flavonoids in C. sativa will provide a comprehensive understanding of its biosynthesis and functions in the plant.

Cannabis has 26 distinct flavonoids (). There are various flavonoids in Cannabis, but the most important ones are orientin, vitexin, luteolin-7-O-glucoside, and apigenin-7-O-glucoside (). Moreover, it contains the potent antioxidant, quercetin (). Cannabinoids are a new type of flavonoid. They are made up of three chemicals found only in Cannabis, i.e., Cannflavin A, B, and C. Cannflavins were discovered in hemp’s leaves and blooms (). Cannflavin A is 30 times more anti-inflammatory than aspirin (). This anti-inflammatory activity can be explained by the reduction of mPGES-1 and 5-LO ().

 

3.2.3 Steroids

Presently, steroid compounds such as campesterol, sitosterol, and stigmasterol have been identified in Cannabis roots (). Moreover, eleven phytosterols have been found in the plant which belongs to the groups stated above (). A trifecta of sterols (campesterol, stigmasterol, and sitosterol) was extracted using hexane from the seed oil of the Indian Cannabis strain (). These three phytosterols were also found in Cannabis smoke, according to research by . Furthermore, β-sitosterol-3-O—Dglucopyranosyl-60-acetate, a known sterol, was first isolated from roots, stem bark, and leaves of Cannabis by using a mixture of methanol and chloroform solvent in the ratio 9:1 (). Sitosterol and sitosterol-D-glucoside were extracted from the plant’s roots in the same study using a mixture of methanol and chloroform solvent in a ratio of 9:1 (). Recent research by , found that higher concentrations of campesterol, stigmasterol, and sitosterol were associated with higher total sterol levels in flowers, leaves, roots, and stems ().

 

3.2.4 Alkaloids

Alkaloids are part of the chemical defense mechanism used by plants to ward off herbivores (). It has been shown that Cannabis contains endogenous indole alkaloids (). For example, alkaloids may be used as analgesics, antibiotics, anticancer drugs, antiarrhythmics, asthma medications, antimalarials, anticholinergics, bronchodilators, laxatives, miotics, oxytocics, vasodilators, psychotropics, and stimulants (). Included in this group of chemicals are morphine, cocaine, nicotine, caffeine, quinine, ephedrine, and many more ().

A group of researchers led by Klein in 1971 researched Cannabis alkaloid combinations and reported the isolation of four different alkaloids, which they called cannabimines A-D (). In the study of cannabinoids, Cannabisativine was the pioneering alkaloid. In 1975, it was extracted from the roots of a Mexican variety of Cannabis sativa that was growing in Mississippi, United States. The compound was extracted using methanol as a solvent. (). These alkaloids were shown to have diuretic, analgesic, anticancer, antipyretic, and antiemetic effects ().

In 1881, Siebold and Bradbury presented their findings on the separation of the alkaloid cannabinine at the British Pharmaceutical Conference (). The next year, in 1883, Hay discovered tetanocannabin, another physiologically active alkaloid. Due to its ability to induce convulsions in amphibians similar to those caused by strychnine, the compound earned its name, a “cannabine alkaloid” product, that was marketed by Merck (of Darmstadt) as early as 1986 ().

 

3.2.5 Fatty acids

Fatty acids carry out their physiological activities due to the involvement of their functional groups in various chemical processes. Some of the fatty acids produced by Cannabis sativa L. can be identified based on their chemical structure (). The fatty acids produced by Cannabis sativa L. have a specific chemical structure that can be distinguished from other fatty acids based on their unique features (). In 1996, Ross and others investigated the fatty acid profile of lipid matter in commercialized Cannabis seeds from several geographical locations. Omega-3 fatty acids such as linolenic acid, isolinolenic acid, and eicosapentaenoic acid; omega-6 fatty acids such as linoleic acid and others such as Caproic acid, caprylic acid, myristic acid, palmitoleic acid, palmitic acid, margaric acid, oleic acid, stearic acid, arachidic acid, isoarachidic acid, and behenic acid are just some of the fatty acids found in commercial Cannabis sativa (). The oil content of the Cannabis plant varies depending on various factors such as the cultivar, growing conditions, and the part of the plant that is being analyzed. In general, the oil content of the seeds of the Cannabis sativa plant is typically around 30%–35% on a dry weight basis (). However, the oil content of other parts of the Cannabis plant, such as the flowers or leaves, is generally much lower (8%–16%) than that of the seeds (). Therefore, the seeds are the primary source of oil extracted from the Cannabis plant for both industrial and nutritional purposes (). Cannabis is not typically considered a significant dietary source of fatty acids. While Cannabis does contain various fatty acids, the concentrations are relatively low compared to other food sources (vegetable oils) that have high concentrations of fatty acids (). Almost half of hulled Cannabis seeds are made up of fat (triglycerides), and the oil that is extracted from them is unique among cooking oils because its triglycerides include very low levels of saturated fatty acids (0.9%) and extremely high levels of polyunsaturated fatty acids (80%) (). Linoleic acid (18:2ω6, 54%–60%), α-linolenic acid (18:3ω3, 18%–23%), and oleic acid (18:1ω9, 7%–12%) are the three primary fatty acids found in Cannabis seed oil.”

Additionally, C. sativa L. seeds, offer nutritional value, since they are composed of around 25% highly nutritious protein and 35% fat (). Hemp oil, pressed from the seeds of the Cannabis plant, is rich in a wide variety of nutrients, including essential fatty acids (EFAs) such as omega-3 and omega-6 fatty acids, vitamins (C, E, B1, B2, B6, B12, and folate), minerals (including calcium, magnesium, potassium, phosphorus, iron, zinc, sodium, and copper), and macronutrients (fat, carbohydrates, fiber, and protein) ().

 

3.2.6 Waxes

Plants create waxes, a class of non-volatile, larger molecular weight, hydrophobic chemicals, to shield their leaves and stem from dehydration and disease (). They may also serve to stabilize defense chemicals, like the phytocannabinoids and terpenes found in Cannabis, which are produced on plant inflorescence (flower heads) (). If compared to Cannabis leaves, the wax content in Cannabis inflorescence is three times higher (). The initial stage in the creation of therapeutic Cannabis products is commonly the extraction of Cannabis inflorescence using organic solvents or supercritical Carbon dioxide (CO2), often resulting in a ‘resin’ with a high wax concentration (). As a result, waxes are a crucial category of phytochemicals to consider during such production. N-pentacosane (C25H52), n-heptacosane (C27H56), n-nonacosane (C29H60), and n-hentriacontane (C31H64) are the most prevalent straight-chain hydrocarbons in Cannabis waxes (). A summary of the structures of other important phytochemicals are provided in (Table 4).

TABLE 4

Structure of other phytochemical classes found in the Cannabis plant.

No Phytochemicals Chemical formula Molecular structure Reference
A Terpenes
1 Myrcene C10H16 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx37.jpg
2 α-Ocimene C10H16 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx38.jpg
3 cis-β-Ocimene C10H16 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx39.jpg
4 D-Limonene C10H16 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx40.jpg
5 α-Terpinene C10H16 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx41.jpg
6 Terpinolene C10H16 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx42.jpg
7 α-Pinene C10H16 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx43.jpg
8 Linalool C10H18O An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx44.jpg
Sesquiterpenes
9 Humulene C15H24 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx45.jpg
10 α-Farnesene C15H24 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx46.jpg
11 β-Farnesene C15H24 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx47.jpg
12 β-Caryophyllene C15H24 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx48.jpg
13 α-Bisabolol C15H26O An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx49.jpg
B Flavonoids
14 Apigenin C15H10O5 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx50.jpg
15 Cannflavin A C26H28O6 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx51.jpg
16 Cannflavin B C21H20O6 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx52.jpg
17 Cannflavin C C26H28O6 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx53.jpg
18 Luteolin C15H10O6 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx54.jpg
19 Orientin C21H20O11 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx55.jpg
20 Vitexin An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx56.jpg
C Steroids
21 Campesterol C28H46O An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx57.jpg
22 β-Sitosterol C29H50O An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx58.jpg
23 Stigmasterol C29H48O An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx59.jpg
D Alkaloids
24 Cannabimines A C21H37N3O2 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx60.jpg
25 Cannabisativine C21H39N3O3 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx61.jpg
E Fatty Acids
26 Caproic acid C6H12O2 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx62.jpg
27 Eicosapentaenoic acid C20H30O2 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx63.jpg
28 Linoleic acid C18H32O2 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx64.jpg
29 α-Linolenic acid C18H30O2 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx65.jpg
30 γ-Linolenic acid C18H30O2 An external file that holds a picture, illustration, etc. Object name is FPHAR_fphar-2023-1200269_wc_tfx66.jpg

4 Traditional and psychedelic properties of Cannabis

The Cannabis plant has been used for centuries and is one of the most beneficial plant genera. Historically, the seeds were used for making oil and pickles, while the leaves were the second most consumed part of the plant and were used in various ways, such as seasoning, flour, and added to meals (). Historically, the psychedelic and recreational use of Cannabis dates to the early 1800 s in tropical parts of the world such as South America and Africa. However, the psychedelic use of the plant did not make it to Europe and America until after the 1800 s (). In countries outside the tropics, the psychoactive components of Cannabis are not present in the variants grown. Cannabis has a long history of medicinal and psychoactive use in India, and it became known in America and Europe in the 19th century for its narcotic and stimulant properties ().

Cannabis cultivation, commercialization, and use as a recreational drug has a significant incidence on a global basis, and often fall within the realm of illicit activities (). However, the comparatively low proportion of psychotropic use does not match the significance of these activities (). The CANNUSE database documents various methods of using Cannabis for psychoactive purposes, including smoking leaves or inflorescences, ingesting preparations made from leaves, inflorescences, and shoots, and consuming preparations of varying intensity such as charas, attar, hashish, ganja, and plant powder ().

The most common ways of administering Cannabis for psychoactive purposes are smoking (56.6%), drinking (37.74%), and eating (5.66%) (). The leaf is the most commonly used part of the plant, accounting for 46.44% of use, even though inflorescences have the highest concentration of THC and other cannabinoids ().

The Cannabis-based food industry mostly uses seeds and derivatives, but other plant parts like sprouts, leaves, and flowers are consumed raw in dishes and drinks. These plant parts contain higher levels of bioactive phytochemicals like polyphenols and cannabinoids than seeds. Ingesting Cannabis makes up 7.29% of all uses, with 58.72% corresponding to traditional meals and 41.28% to traditional beverages. Seeds are the most common plant component used for food, and this association is statistically significant. Seeds are popular among Asian senior citizens due to their high protein content and low glycemic index (). Cannabis seeds can be found in different forms such as energy bars, chocolates, flour, baked products, milk, and flavoring sauce. The plant’s sprouts, leaves, and flowers are also consumed raw in dishes and drinks ().

5 Pharmacological potential of Cannabis

The prospect of using Cannabis for the treatment of a wide variety of diseases is promising now that the Δ9-THC and endocannabinoid systems, receptors, enzymatic systems, and physiological effects have been identified (). It has been effective in the treatment of gastrointestinal disorders, infections, psychosis, anxiety, depression, anorexia, and cachexia, as well as in the treatment of asthma (bronchiectasis), pain, musculoskeletal disorders, tumor, and arthritis (). It also has antiglaucoma, antimicrobial, and antiemetic properties. Additionally, it has anti-obesity and anti-cancer properties (). Clinical studies have investigated the effects of Δ9-tetrahydrocannabinol (THC) on a variety of diseases, such as AIDS, advanced cancer, glaucoma, nausea, chemotherapy-induced vomiting, itching, allergies, psychiatric symptoms, and movement abnormalities (). Some of these pharmacological potentials are summarized below in Figure 6.

An external file that holds a picture, illustration, etc. Object name is fphar-14-1200269-g006.jpg

Pharmacological potential of Cannabis.

5.1 Antimicrobial activities of Cannabis sativa extracts

Cannabinoids’ antimicrobial property has been known since the 1950s when the first reports appeared (). The bactericidal activity of C. sativa could not be linked to a single compound since these trials were performed before the phytochemistry of Cannabis was extensively known (). It was accomplished in 1976 when it was discovered that both Δ9-THC and CBD are bacteriostatic and bactericidal against a panel of Gram-positive bacteria (). Antibacterial activities of C. sativa extracts, including essential oils and those obtained from petroleum ether, methanol, and hot water, have also garnered significant attention (). The oil from the seeds of the plant was extracted using petroleum ether and methanol and was found to exhibit antibacterial activity against Gram-positive bacteria. Interestingly, while the petroleum ether extract was found to be ineffective against Pseudomonas aeruginosa, it was observed to have some mild activity against Gram-negative bacteria (). The principal components of C. sativa ethanol extracts showed moderate effectiveness exclusively against both clinical samples and non-clinical methicillin-resistant staphylococcus aureus (MRSA) infection isolates, as was earlier shown by .

 found that ethanol Cannabis. sativa seed extracts inhibited S. aureus biofilm development, suggesting that these extracts may have significant use as food and cosmetic preservatives. Also,  discovered that cannabinoids are more successful than commercial toothpaste like Oral B and Colgate in reducing the bacterial colony count in dental plaque, suggesting that C. sativa-derived chemicals might be employed for oral care applications. Medical, aesthetic, veterinary, agricultural, and culinary uses of a Δ9-THC-free essential oil of C. sativa are all possible and are now being researched. Naringenin, a flavanone, was shown to contribute to the oil’s mild antibacterial efficacy and antibiofilm activity when tested against many strains of S. aureus (). Helicobacter pylori, a Gram-negative bacteria, was likewise shown to be susceptible to the antimicrobial effect, although no antifungal activity was detected ().

Several S. aureus and Streptococcus isolates were shown to be susceptible to CBD and Δ9-THC, with MIC in the range of 1–5 g/mL (). This bactericidal action, however, was diminished in the presence of horse serum, most likely because of the cannabinoids binding to plasma proteins ().  examined a variety of cannabichromene analogues for their antimicrobial and antifungal effects. Activity against B. subtilis and S. aureus seems to depend on the n-pentyl chain meta to the alcohol group ().

In addition to reducing biofilm formation, the use of certain Cannabis-infused medicines was found to modify other biofilm-associated virulence factors such as cell aggregation, hydrophobicity, membrane potential, and spreading ability (). These medicines can be used in conjunction with standard antibiotics like ampicillin and gentamicin to treat MRSA biofilm infections that have shown resistance to other treatments. CBD has also been shown to enhance the antibacterial action of the peptide medication bacitracin against Staphylococcus species, L. monocytogenes, and E. faecalis (). Several Cannabis analogues were tested by  and proved to be effective against MRSA USA300 and E. coli. Several commonly used cannabinoids showed moderate to excellent activity; these findings were generally consistent with those of prior research (vide supra). The MIC values increased by up to a factor of four ().

CBD was also found by  to be a synergistic agent when combined with different antibiotics. CBD was found to significantly inhibit the release of membrane vesicles by Gram-negative pathogens, which are involved in bacterial communication. When used in conjunction with erythromycin, vancomycin, rifampicin, kanamycin, or colistin, CBD’s antibacterial action was amplified against E. coli VCS257. These findings suggest that these cannabinoids may be used to increase efficiency and broaden the action of currently available antibiotics, which is an important development in the field of antibiotic resistance.

The Cannabis plant and its secondary metabolites have also been studied for their antifungal capabilities. Some articles claim that Cannabis extracts may be effectively utilized in the control of pathogenic fungi, albeit this impact has not been as widely explored as its antibacterial properties ().  showed that ethanol and petroleum extract from Cannabis leaves effectively inhibited the growth and development of Candida albicansCandida krusei, and Aspergillus niger. In both instances, the concentration of the leaf extract was 10 times greater compared to the antifungal antibiotic (Nystatin), although the zone of inhibition was substantially larger with the antifungal antibiotic. The antifungal properties of Cannabis sativa L. seed oil and whole-plant extracts of petroleum ether and methanol were investigated by . However, while the whole-plant petroleum ether extract exhibited some action against C. albicans, the seed extract and whole-plant methanol extract were ineffective against the two fungi tested. For their ability to prevent the spread of the seed-borne phytopathogenic fungus Alternaria spp.;  examined the antifungal properties of extracts from 11 weed varieties. Although all plants showed some antifungal activity, some were far more effective than others. The percentage of mycelial development that Cannabis sativa L. was able to halt was not the highest among the plants analyzed, but it was still rather high. The acetone-based extract proved to be the most effective antifungal agent among 5 distinct extract types. Some properties are summarized in Table 5 below.

TABLE 5

Antibacterial potentials of Cannabis.

S/N Cannabis material Solvent used MIC Type of assay Pharmacological activity Country Reference
1. Hemp essential oils Methanol 0.25-32 µg/ml MIC Antibacterial activity Italy
2. Hemp fiber Acetone 5.64 x10-7g of antibiotics/100 mg of ester) MIC Antibacterial activity Italy
3. Oil of seeds, whole plant extract Methanol 12.5-50 µg/ml MIC Antimicrobial activity Sudan
4. Leaf extract Distilled water 5.60-25.44 mm Agar well diffusion assay Antibacterial India
5. lipophilic extracts of Cannabis products propylene glycol 0.00125-1.25 μg/ml MIC Antibacterial activity U.S.A
6. Leaf extract Ethanol, hot water 9.2-25.7 mm Agar well diffusion assay Antibacterial activity Pakistan
7. Aqueous leaf extract Water 6-13 mm Agar well diffusion assay antibacterial activity Romania
8. Cannabinoids acetone 5 mg/ml MIC Antibacterial activity Italy
9. Cannabigerol Aqueous 4 μg/ml MIC Antibiotic activity Canada
10. Leaf extract Ether and acetone extract 42 μg/ml MIC Bactericidal activity India

5.2 Anticancer activities

Cannabinoids (CBs) are active metabolites in Cannabis sativa, and they are responsible for the plant’s medical effectiveness (). CB derivatives have been shown to suppress the growth and survival of multiple forms of cancer cells. The underlying processes of the effects may be unique to each type of cell, and CBs can target tumors specifically to disrupt signaling and biological processes, leading to growth pause, cell death, and migratory blockage (). CBs may also have indirect effects on the tumor microenvironment, immune response, and vascularization suppression. Both direct and indirect anticancer effects of CBs have been studied (). In recent decades, there have been significant studies on the purity, efficacy, and therapeutic utility of Cannabis and cannabinoids (CBs) in preclinical and clinical cancer models. CBs have shown promise in treating and diagnosing cancer-related symptoms. THC, a type of CB, has been observed to accelerate the death of tumor cells compared to healthy cells. Long-term rat models have shown that Δ9-THC exhibits little toxicity and has no discernible impact on hematological parameters, general health, or mortality (). Non-psychoactive CBD has been studied as a potential anticancer drug due to its action in vitro and in vivo against tumor cells produced from CBs found in C. sativa. Meanwhile, THC was administered to terminal cancer patients. However, the precise chemical pathways by which CBs exert their anticancer effects are not completely understood suggesting that more research involving the antitumor effects of CBs should be done. (). Secondly, regulation of the proinflammatory nuclear factor kappa B pathway has been linked to a tumor’s prosurvival impact, as well as chemoresistance in cancer cells, although the route is independent of Akt. Epidermal growth factor (EGF) signaling activation is essential for tumor cell growth, survival, and progression (). In addition to its ability to destroy cancer cells, Cannabis sativa extract has anti-nausea and anti-vomiting properties that are beneficial for cancer patients. CBD has been found to reduce proinflammatory pathways by decreasing EGF signaling pathway activity (). By activating the TRPV channel and increasing endoplasmic reticulum stress, CBD can induce cancer cells to self-destruct. CBD also binds to and activates GPR55, which suppresses ERK pathway activation and halts cancer cell growth. As a result, multinational corporations are now offering medications containing cannabinoids in the form of plant extracts or volatile oils. Sativex, a standardized extract of Cannabis sativa L., has been licensed in Canada for the treatment of pain (). Various anticancer activities of cannabis found in liver, breast, bladder and lung are summarized below (Figure 7).

An external file that holds a picture, illustration, etc. Object name is fphar-14-1200269-g007.jpg

Anticancer activities of the Cannabis.

 

5.2.1 Liver cancer

Liver cancer is a leading cause of mortality and suffering worldwide (). CBs have been found to have anticancer effects by triggering apoptosis and suppressing telomerase activity. Low molecular weight hemp peptides have been shown to induce apoptosis, decrease cell viability, and reduce cell motility in Hep3B human liver cancer cells without modifying the baseline overexpression of cleaved caspase 3 and Bad, or downregulation of antiapoptotic Bcl-2 (). This strategy induced Akt and GSK-3 phosphorylation, followed by downregulation of β-catenin, demonstrating that β-catenin’s signaling modulation is the mechanism governing the anticancer activity. While further research is needed, these results suggest that hemp peptides may serve as a promising therapy for liver cancer ().

 

5.2.2 Breast cancer

Breast cancer is the deadliest disease affecting females worldwide (). CBs have been found to significantly inhibit the proliferation of breast cancer cell lines, including human MDAMB231-luc-D3H2LN cells, which are sensitive to both 9-THC and CBD. CBs inhibited tumor invasion and metastasis in animal models and reduced EGF-induced proliferation and chemotaxis in triple-negative breast cancer cells (). CBD inhibited Id-1 receptor expression, cell proliferation, and invasion in breast cancer cells. In an athymic nude mouse model of breast cancer cells, CBD and CBG decreased tumor volume and promoted apoptosis. Δ9-THC was also found to reduce the growth of breast cancer cell lines (). At a concentration of 5 mM, CBD destroyed breast cancer cells in cell culture by cell-autonomous apoptosis and autophagy without harming normal cells, with relatively insignificant effects on TRPV1, CB1, and CB2 receptors ().

CBD’s in vivo antimetastatic activity was evaluated in syngeneic BALB/c mice by injecting 4 T1 breast cancer cells into the tail vein. CBD at 1 and 5 mg/kg suppressed both primary tumor growth and the number of metastatic foci by regulating cell migration through the activation of the ERK enzyme (). CBD at 5 mg/kg body weight also suppressed tumor development and lowered tumor volume in athymic nude mice with breast tumor xenografts, increasing the animals’ median survival time ().

 

5.2.3 Bladder cancer

Smoking cigarettes is a major contributor to the development of bladder cancer (). Numerous polls have found that a large percentage of cigarette smokers also regularly consume Cannabis (). To determine the link between Cannabis and cigarette use and the development of bladder cancer in men in California,  conducted epidemiological research. They interviewed 84,170 males to find out about their habits like smoking and using Cannabis. The study indicated that while smoking alone was linked to a 15% increased risk of getting bladder cancer, Cannabis use alone was linked to a 45% lower risk. However, more rigorous studies are needed to thoroughly assess the plant’s medical potential in the treatment of bladder cancer.

 

5.2.4 Lung cancer

Small-cell and non-small-cell lung cancers are the most common forms of lung cancer, with tobacco use, family history, and exposure to radon gas increasing the likelihood of developing the disease (). CBs have been studied in vivo for their efficacy against lung cancer, and CBD therapy has been found to inhibit tumor growth, invasion, and metastasis in mice bearing xenografts of A549 cells (). In vitro, investigations using lung cancer cell lines A549, H358, and H460 showed that CBD upregulated the antimetastatic protein ICAM-1, which is hypothesized to reduce tumor development through an immunosurveillance mechanism ().

CBD was found to increase TIMP-1 and ICAM-1 expression in a dose-dependent manner in lung cancer cell lines and inhibited the spread and invasion of human lung cancer xenografts in mice, partially due to the increase in ICAM-1 and TIMP-1. It triggered apoptosis through PPAR-g and COX-2 in human metastatic lung cancer cells and caused tumor regression in A549 xenografted mice (). In human metastatic lung cancer cells and cancer cell lines A549 and H460, CBD and THC boosted ICAM-mediated lymphokine-activated killer cell adhesion and cancer cell lysis, increasing the lung cancer cells’ susceptibility to being lysed by LAK cells. Further research is needed to confirm Cannabis’ protective effect against lung cancer ().

5.3 Epilepsy

As a neurological condition, epilepsy is characterized by aberrant brain activity and frequent seizures (). During the first decade of life, this affects about 1 in 150 children (). Epileptic encephalopathies are characterized by refractory seizures, severe electroencephalographic abnormalities, and developmental impairment (). Clinical evidence for the use of CBs in the management of epilepsy has been backed up by preliminary studies ().  reported that using CBs in a mouse model of Dravet syndrome led to a decrease in autistic-like social deficiencies, suggesting that these drugs’ benefits extend beyond seizure control.

Clinical investigations have shown that CBD and cannabidivarin (CBD’s propyl version) have anticonvulsant qualities, although the particular processes by which they do so remain unknown (). A large, prospective, single-center, open-label study of CBD for the treatment of medication-resistant epilepsy in children and adults showed striking improvements in disease phenotype in response to CBD therapy for 72 children and 60 adults (). In addition, EPIDIOLEX®, a CBD medicine derived from Cannabis, was recently licensed by the FDA for the first time to treat Lennox-Gastaut syndrome and Dravet syndrome, two extremely uncommon but extremely serious forms of epilepsy (). These results suggest that CBs including CBD may be useful for the treatment of epilepsy and other neurological disorders (). Furthermore, CBD proved beneficial in reducing seizure frequency in a comprehensive trial and meta-analysis of its efficacy for treatment-resistant epilepsy ().

5.4 Parkinson’s disease

There are motor and non-motor symptoms associated with this kind of neurodegenerative disease. Non-motor symptoms of Parkinson’s disease, such as constipation, sleep issues, anxiety, and sleep instability, were studied by , who reviewed the data of many trials to determine whether CBD may be helpful. Dopamine-containing neurons in the basal ganglia were shown to deteriorate in Parkinson’s disease, which may be linked to mitochondrial malfunction, oxidative stress, and impaired protein breakdown in the affected cells (). Several studies have found a correlation between the endocannabinoid system (ECS) and Parkinson’s disease (). The ECS consists of cannabinoids (CB) receptors, i.e., CB1 and CB2, their ligands, and the enzymes responsible for their production and metabolism (). The basal ganglia of the brain are where endocannabinoids are most concentrated. By activating or inhibiting CB1 or CB2, CBD contributes to the lowering of dopamine levels. CBD’s sedative action has also been studied, with mixed results (depending on dosage and mode of administration) including enhanced sleep delay and alertness (). Rats given either high or moderate dosages of CBD in an experiment by  slept longer and for longer periods thereafter.

One study found the effectiveness of Cannabis-based medicinal extracts v/s placebo for the treatment of individuals with spinal cord injury (SCI) (). Peppermint oil, 0.05% (v/v), ethanol, and propylene glycol (50:50) were the excipients in a THC (27 mg/mL): CBD (25 mg/mL) extract of Cannabis sativa L. After receiving treatment, patients reported significantly higher ratings of central neuropathic pain on the 11-point numerical rating scale, with a negative number indicating an increase in pain from pre-treatment levels.  also did a scoping assessment of the literature on Cannabis’s effect on SCI pain severity. Variations in methodology, such as the lack of standardized dosage regimens, modes of use, and trial length, led to contradictory findings across the study’s articles reporting on five treatment studies. Consistent and sufficient data is, therefore, lacking to form accurate conclusions on the efficacy of Cannabis in lowering the pain intensity associated with SCI, indicating that more study is needed in this area.

5.4 Gastrointestinal disorders

Cannabis is used by inflammatory Bowel Disease (IBD) patients to alleviate symptoms and improve their quality of life. Endocannabinoids (ECS) help in maintaining intestinal homeostasis, which requires a combination of centrally and peripherally mediated actions (). The ECS consists of endocannabinoids, enzymes that make and break down endocannabinoids, and CB receptors that mediate endocannabinoid effects (). The enzymes responsible for the breakdown of endocannabinoids are fat acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL). However, more research is needed to understand the role of the ECS in IBD and the effects of Cannabis on these conditions ().

The endocannabinoid system (ECS) is present throughout the gut and controls several digestive processes such as GI motility, inflammation, and immune response. Cannabis can potentially impact these processes by activating the receptors in the ECS, leading to an increase in food intake and metabolic processes like lipolysis and glucose metabolism ().

Cannabis is used for various gastrointestinal (GI) ailments, including enteric infections, inflammation, motility difficulties, emesis, and stomach discomfort. Endocannabinoids can inhibit proinflammatory mediators such as IL-1β, TNF-α, and nitric oxide, reducing the cellular pathways leading to the coordinated inflammatory reactions in IBD (). Cannabis formulations have been shown to significantly reduce the severity of colitis in experimental animal models of IBD. CBs can regulate GI motility, which has paved the way for the development of a new class of antibiotics that can treat a wide range of GI conditions, including colitis, Crohn’s disease, gastric ulcers, paralytic ileus, IBS, colon cancer, and others ().

The ECS can be useful in managing irritable bowel syndrome-diarrhea (IBS-D) and irritable bowel syndrome-constipation (IBS-C) by affecting motility and secretion through CB1 agonists. CB2 receptors can be used to treat IBS-D because they are overexpressed during stomach inflammation (). The ECS plays an inhibitory role in the GI tract by suppressing motility and secretion and controlling pain perception. CB receptor activation can protect against colitis, and inhibiting breakdown enzymes (FAAH or MAGL) can reduce inflammation. Inhibiting the enzyme that produces 2-AG (DAGL) can regularize feces in constipation-prone animals and reduce 2-AG levels ().

Studies have shown that patients with Crohn’s disease have increased CB receptors and/or endocannabinoids in their intestines. CB1 and/or CB2 agonist treatment has been found to reduce colitis in animal models of inflammatory bowel disease (). Clinical research on the use of Δ9-THC to treat Crohn’s disease has shown promising results, but further studies are needed to determine appropriate doses, modalities of usage, patient populations that would benefit, and long-term exposure risks through randomized, controlled, and prospective clinical studies ().

Cannabis’ potential in the food industry

According to Cannabis cultivars can be used in food production in Europe if the amount of ∆9-THC and ∆9-THCA in unrecognized blooming or fruiting plant tips is less than 0.2% dry matter. This requirement is in place to prevent the production of edible Cannabis products, but the consumption of hemp seeds is still allowed. In November 2015, the European Union passed Regulation 2015/2283, which designates certain hemp extracts and parts as “novel foods” ().

There’s a wide variety of baked goods, pizza, oil, beer, milk, chocolate, ice cream, and snacks made with Cannabis seeds (). Cannabis-related food exports from Italy are worth 50 billion euros and make a big difference in the country’s economy (). The hemp-based agri-food chain may be the biggest step forward for this industry. Demand for hemp-based foods has increased fivefold from 2017 levels (). Hemp seed flour is a healthy alternative to wheat flour. Although it tastes rough and rustic, hemp flour has 21% fewer calories than regular oat flour (). Celiacs can eat it without worry because it does not contain gluten (). According to , hemp has only 25% protein and 65% edestin. Recent studies by  have shown that, like animal proteins, edestin provides all eight essential amino acids. These findings reveal that Cannabis has the potential to make the world’s food supply much safer by lowering the need for animal protein.

Cannabis’ potential in the Cosmetics industry

Cannabis seeds are frequently used in traditional cosmetic treatments, especially for hair care, due to their high oil content.  studied the effect of Cannabis seed oil on the strength of hair and nails. Cannabis stems are also highly valued, particularly in Pakistan ().

Moreover, Cannabis seed oil is often used as a hair food due to its rich nutritional profile. The oil is particularly high in polyunsaturated fatty acids, such as omega-3 and omega-6 fatty acids, which are essential for maintaining healthy hair (). These fatty acids help to nourish and moisturize the hair, making it softer, smoother, and more manageable. They also help to prevent hair breakage, split ends, and dryness, which can lead to hair loss over time ().

In addition to its fatty acid content, Cannabis seed oil is also high in carotenoids, which have been shown to promote hair growth and improve hair health (). Cannabis seed oil can be used in a variety of ways as a hair treatment. It can be applied directly to the scalp and hair as a hair mask, left on for several minutes or overnight, and then rinsed off with shampoo and conditioner. The oil can also be added to shampoos and conditioners to enhance their moisturizing and nourishing properties (). Carotenoids, such as β-carotene, can help to strengthen the hair shaft and protect it from damage caused by UV radiation and other environmental stressors. They can also help to improve the elasticity and overall appearance of the hair ().

The endocannabinoid system (ECS) in the skin plays an important role in regulating cell differentiation, development, survival, inflammation and immune responses, pain perception, and hair growth (). Disruption of the ECS can lead to various dermatological problems (). The ECS is controlled by CB1 and CB2 receptors, which are found in different cells in the skin. CB1 is expressed in hair follicle cells, immune cells, and keratinocytes and regulates pain, neuronal activity, and inflammation. CB2 is found in sensory neurons, immune cells, sebaceous glands, and keratinocytes and also regulates inflammation (). Activating CB1 has been shown to prevent keratinocytes from producing pro-inflammatory cytokines and maintaining the integrity of the epidermal barrier ().

Cannabis seed oil is a rich source of carotenoids, such as β-carotene, lutein, and zeaxanthin, which are easily absorbed by the skin (). These carotenoids have antioxidant properties that can combat free radicals and protect against UV light (). β-carotene can also prevent the activation of pro-inflammatory cytokines by UV-B radiation, thus exhibiting anti-inflammatory effects. Carotenoids can also improve skin hydration, promote wound healing, and stimulate the production of collagen and elastin by activating fibroblasts (). The Cannabis seed oil has a high concentration of chlorophyll, which can range from 100 μg/g to 230 μg/g, depending on the extraction process (). Chlorophyll has been shown to promote tissue growth and have antibacterial properties, making it potentially useful in wound healing and treating skin problems like acne, eczema, and ulcers. The green pigment in hemp seed oil comes from chlorophyll ().

The Cannabis seed oil contains flavonoids, terpenes, carotenoids, chlorophylls, and phytosterols that contribute to its anti-inflammatory and anti-aging properties. The oil is quickly absorbed and does not clog pores, making it useful in formulations designed to soothe the skin, such as sunscreen creams and lotions. The natural presence of chlorophyll makes it potentially effective for wound healing and treating skin problems. Topical creams and ointments containing Cannabis seed oil have potential applications in anti-aging skincare (). The various uses are summarized below in Figure 8 below.

An external file that holds a picture, illustration, etc. Object name is fphar-14-1200269-g008.jpg

Cannabis potential in the food industry.

8 Significance of Cannabis cultivation to agriculture and environment

Cannabis sativa L. was first cultivated for textile fiber in Western Asia and Egypt. It later spread to Europe and was eventually brought to North America in 1,606, beginning with Port Royal in Canada (). Cannabis farming has a low negative environmental impact because it can proliferate, kill weeds, and does not require pesticides. It does not have parasites that are only beneficial for one plant, which helps with pollination and improves soil fertility (). Although Cannabis sativa was traditionally used as a source of stem fiber and was rarely considered a narcotic, it has been one of the world’s oldest sources of textile fibers for more than 6,000 years. Its use as an oil crop was limited for most of its existence ().

Hemp was introduced for fiber production in Western Asia and Egypt between 1,000 and 2000 BC and later spread to Europe. After 500 AD, the cultivation of hemp became widespread throughout Europe ().  also provide an excellent overview of the historical and cultural use of CannabisCannabis is considered an environmentally friendly crop in recent times, with added interest in its cultivation due to its potential to help combat climate change and desertification. As a result, the EU has proposed Cannabis cultivation as a potential new star in European agriculture, aligning with EU 2030 goals of reducing greenhouse gas emissions by 40% from 1990 levels. ().

Cannabis can reduce the amount of Carbon dioxide (CO2) in the atmosphere, and it is particularly effective due to its high rate of growth. This makes it a valuable agricultural species for reducing greenhouse gases. However, the current atmospheric CO2 level is still much higher than pre-industrial levels, so further research is needed to find more effective ways to reduce carbon emissions (). The use of slow-release nitrogen fertilizers in which urea is combined with an aldehyde like nitroform, methylene urea, or urea formaldehyde is recommended for Cannabis farming due to their positive impact on plant growth and seed quality (). In contrast, the use of synthetic fertilizers like ammonium nitrate can increase greenhouse gas emissions like nitrous oxide (N2O), which contributes to global warming and is a significant source of emissions in some countries (). Cannabis has a different eco-physiological trait than cotton and kenaf, where it is not as efficient in using nitric nitrogen. However, it excels at photosynthetic metabolism at low nitrogen levels (). Slow-release nitrogen fertilizers, such as urea-formaldehyde, can reduce the amount of N2O released during the growth cycle, which is a significant contributor to greenhouse gases. Additionally, Cannabis stores CO2 in its biomass, making it a potentially climate-friendly crop that can help prevent climate change ().

Growing Cannabis has the potential to set up new supply chains due to the versatility of the different plant parts. This could be beneficial for farmers, the environment, and human health, making it an important plant for the new green economy (). Various industries can use different parts of the plant: seeds for the agri-food industry, canapulo for the green building sector, fiber for the textile industry, and inflorescences and roots for the pharmaceutical and para-pharmaceutical industry through the extraction of bioactive molecules ().

Cannabis requires nutrients and water to grow, with varying daily water use depending on location, soil, weather, and growing methods (). Outdoor Cannabis cultivation in California uses an average of 5.5 gallons of water per day per plant, according to a survey (). Agricultural usage, population growth, and climate change are expected to worsen water shortages, which will affect the Cannabis industry and harm the environment (). The amount of water needed for Cannabis plants to survive and thrive is a concern for the industry (). Cannabis cultivation, particularly illegal cultivation, can lead to water contamination. The plant requires increased levels of nitrogen, phosphorus, and potassium for optimal growth, but little research has been done on how this affects water quality globally (). The use of pesticides, such as herbicides, insecticides, fungicides, nematocides, and rodenticides, can also contribute to water contamination when not properly checked, posing a threat to the environment (). Cannabis cultivation can lead to the contamination of soil, surface water, and groundwater due to the leakage of nitrogen and pesticides from runoff or rain (). This can harm both humans and crops that consume these chemicals. The contamination of water caused by Cannabis cultivation can also impact the environment where other important irrigated crops are grown (). However, it is difficult to link Cannabis farming practices to water pollution without proper measurement of water quality and chemical levels. Thus, legislation is needed to protect the environment from pollutions arising from commercial Cannabis cultivation. In this regard, Canada has some of the strictest environmental regulations for growing Cannabis indoors to mitigate the impact on the environment.

, report that Cannabis production is directly linked to soil erosion, especially on steep slopes that are more prone to erosion. The cutting down of trees and clearing of forests for Cannabis cultivation exacerbates soil erosion. However, durable greenhouses can help prevent soil erosion by avoiding the need for massive clearings that expose soil to erosion ().

Cannabis can help address biodiversity loss by attracting pollinating insects due to its terpenoid essence, and its pollen can be blown up to 3 km, increasing the diversity of agroecosystems (). The plant blooms at different times and provides ample pollen, making it an important source of food for bees (). By creating a microclimate that is beneficial for pollinators, Cannabis contributes to the conservation of biodiversity, which is essential to the health of the planet (). Another potential application of Cannabis is a bioremediation crop that can absorb and store heavy metals from the soil, making it effective in cleaning contaminated soil (). Tainted soil fertilizer is a common source of arsenic, cadmium, lead, and mercury.  found that Cannabis sativa may absorb lead and cadmium from manure-contaminated soils.

9 Risk and safety of Cannabis

The widespread acceptance of medical and recreational Cannabis usage in recent years has contributed to a surge in the drug’s popularity in several countries (). There is an ongoing debate among experts regarding the safety of the plant. While in some parts of the world, it is viewed as a helpful medicine, in other parts it is seen as a dangerous substance if taken in large amounts, particularly when it comes to the consumption of Cannabis-containing foods or beverages (). Research suggests that certain genetic variants may increase the risk of mental health problems in individuals who use Cannabis due to its impact on brain development, including neuroanatomical alterations, respiratory problems, metabolic and neurotransmitter functioning, and neuronal activation ().

Second, Cannabis has been linked with negative effects on conditions like cardiopulmonary arrest, coronary artery disease, transient ischemic attack, and cannabis arteritis. Additionally, exposure to high amounts of THC for recreational use has been found to negatively affect various physiological systems, including ophthalmological, gastrointestinal, respiratory, immunological, and hormonal systems (). However, serious poisoning is rare among adults and negative side effects are reported by only a small percentage of users. A study found that only 3.24% of participants reported negative side effects from using Cannabis. The flower was used in 42.86% of cases, and the leaf was used in 40.8% of cases. The study identified 45 different side effects, but only one mention of death ().

Furthermore, ancient medicine recognizes both the benefits of Cannabis and the risks of overuse (). Research has found that Cannabis has both stimulating and sedative effects, including increased appetite and aphrodisiac effects as well as the ability to cool the body (). However, according to , long-term use can have unintended side effects such as stomach pain, thinning skin, depression, inability to work, and dropsy (a buildup of water in the body) (). Using the right amount of Cannabis is important for both medical and recreational purposes. In 2021, the United Nations Office on Drugs and Crime (UNDOC) removed Cannabis from Schedule IV, but it remains on the Schedule I list due to insufficient data on its effects (). For instance, reports have linked Cannabis use to the growth of tumors, including in children whose mothers’ used marijuana during pregnancy. Depending on the dose and length of use, Cannabis can also cause cancer, birth defects, and genetic changes. In addition to harming mental health, Cannabis use can negatively impact respiratory, cardiovascular, and bone functions ().

One of the main risks associated with Cannabis use is the potential for overconsumption, particularly when consuming edibles or other foods infused with Cannabis (). This is because the effects of ingested Cannabis can take longer to manifest and last longer as compared to when Cannabis is smoked or vaporized, leading users to inadvertently consume more than intended (). Overconsumption of Cannabis can cause severe side effects, including vomiting, nausea, anxiety, paranoia, and, in the extreme cases can lead to hospitalization (). A study found that the rate of emergency department visits related to Cannabis-containing edibles increased significantly after legalization in Colorado ().

Moreover, one of the major safety concerns associated with Cannabis use is the potential for contamination with biological, physical, or chemical contaminants (). Microbial contamination of Cannabis-containing foods for instance can lead to foodborne illness, especially in persons with weak immune systems or other underlying health conditions. In one study, researchers analyzed a variety of Cannabis-infused food products and found that many were contaminated with high levels of bacteria including E. coli and Salmonella. In other studies, a significant percentage of Cannabis products tested were found to be contaminated with pesticides, mycotoxins, and heavy metals above the legal limit (). In addition to these risks, there is also the potential for adverse drug interactions between Cannabis and other medications, particularly those that are metabolized by the liver (). Cannabis can interact with certain medications, such as blood thinners and antidepressants, leading to unintended side effects or reduced effectiveness of these drugs (). Furthermore, there are concerns about the potential for Cannabis to interact with other medications or supplements (). For example, a study found that consuming grapefruit juice with Cannabis-containing products can increase the levels of THC in the blood, potentially leading to an increased risk of adverse effects ().

Another issue is the lack of standardized dosing guidelines for Cannabis-containing foods (). Because the potency of these products can vary widely, it can be difficult for consumers to know how much of a particular product they should consume to achieve the desired effects without risking overconsumption (). This has led to instances of accidental overconsumption and adverse effects, particularly in the case of edibles, which can be deceivingly potent (). Another concern is the potential for Cannabis-containing foods to be appealing to children and young people. As these products become more widely available, there is a risk that they could be mistaken for regular food items and ingested by children, potentially leading to serious adverse effects ().

To address this issue, some jurisdictions have implemented packaging and labeling regulations for Cannabis-containing products to make them less appealing to children. In the United States, for example, the FDA requires that all Cannabis-containing food products be labeled with the statement “Keep out of reach of children” and include a warning that the product contains Cannabis (). Some states such as Colorado, California, and Washington have gone further, requiring that products be packaged in child-resistant containers or that the packaging be opaque or non-descript to reduce their appeal to children. Similarly, in Canada, the Cannabis Act requires that all Cannabis-containing products be packaged in child-resistant containers and display a standardized warning label that includes the THC content and other relevant information (). In addition, the act prohibits the use of branding and labeling that may appeal to children, such as cartoon characters or bright colors (). In Australia, Cannabis-containing products must be packaged in opaque, child-resistant packaging and display warnings about the potential health risks associated with consumption (). In the Netherlands, all Cannabis-containing products must be labeled with a warning that they are not intended for consumption by children or minors ().

10 Conclusion and future perspectives

Cannabis is a versatile plant with many therapeutic uses. The current review has shown that it contains compounds with numerous therapeutic benefits, such as antioxidants, cytotoxic agents, and antibacterial, antifungal, anticancer, antidiarrheal, neuroprotective, and hepatoprotective properties. Cannabis sativa can be used in a variety of industries including biomedicine, agriculture, food, and cosmetics.

These bioactivities are attributed to its phytoconstituents, including cannabinoids, terpenes, flavonoids, alkaloids, and steroids, which highlight its potential as a source of medicinal agents. In addition to its medicinal uses, Cannabis has diverse applications in agriculture as fibre, food (as a source of protein, fiber, and functional foods), and cosmetics (as an active ingredient or oil). Although the available literature demonstrates the endless potential of Cannabis in these areas, more extensive research is needed to uncover the many unknown chemical substances with medical value. While empirical investigations of the plant have already been established, further studies should aim to identify and test these substances for their therapeutic benefits in treating various ailments.

In addition, Cannabis sativa L. is often overexploited as a recreational drug despite its potential uses in various fields due to its easy accessibility. Studies have confirmed its toxicity to brain development and the nervous system, but its extensive traditional use presents challenges in controlling its impact. Engaging users to understand the plant’s potential and training growers in cultivation, extraction, and production can help reduce overexploitation. Policies are also needed to protect and utilize the benefits of Cannabis plants. Community engagement, planning, monitoring, evaluation, and implementation can all help in this effort.

Funding Statement

This research received external funding from Beehigh Vital Elements Inc., NL, Canada.

Author contributions

Conceptualization, EF; methodology, EF; resources, EF; writing original draft preparation, EF; writing—review and editing, EF, MC, AS, RJ, TP, CM, and RT; supervision, CM and RT; funding acquisition, CM and RT. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that this study received funding from Beehigh Vital Elements Inc. Corner Brook, NL, Canada The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • Adams J. R. T. C., Jones L. A. (1973). Long-chain hydrocarbons of cannabis and its smokeJ. Agric. Food Chem. 21, 1129–1131. 10.1021/jf60190a005 [PubMed] [CrossRef[]
  • Ahmed S. A., Ross S. A., Slade D., Radwan M. M., Zulfiqar F., Elsohly M. A., et al. (2008). Cannabinoid ester constituents from high-potency Cannabis sativaJ. Nat. Prod. 71, 536–542. 10.1021/np070454a [PMC free article] [PubMed] [CrossRef[]
  • Aizpurua-Olaizola O., Soydaner U., ÖZtüRk E., Schibano D., Simsir Y., Navarro P., et al. (2016). Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypesJ. Nat. Prod. 79, 324–331. 10.1021/acs.jnatprod.5b00949 [PubMed] [CrossRef[]
  • Akhtar N., Ali A., Bashir U., Haider M. S. (2016). Bactericidal action of crude leaf extracts of common weedsPak. J. Weed Sci. Res. 22, 157–167. []
  • Akram M., Iqbal M., Daniyal M., Khan A. U. (2017). Awareness and current knowledge of breast cancerJ. Biol. Res. 50, 33–23. 10.1186/s40659-017-0140-9 [PMC free article] [PubMed] [CrossRef[]
  • Akyeampong E. (2005). Diaspora and drug trafficking in west Africa: A case study of GhanaAfr. Aff. 104, 429–447. 10.1093/afraf/adi015 [CrossRef[]
  • Al Ubeed H. M. S., Bhuyan D. J., Alsherbiny M. A., Basu A., Vuong Q. V. (2022). A comprehensive review on the techniques for extraction of bioactive compounds from medicinal cannabisMolecules 27, 604. 10.3390/molecules27030604 [PMC free article] [PubMed] [CrossRef[]
  • Albala K. (2003). Food in early modern Europe. Westport, Connecticut, USA: Greenwood Publishing Group. []
  • Alexander A., Smith P. F., Rosengren R. J. (2009). Cannabinoids in the treatment of cancerCancer Lett. 285, 6–12. 10.1016/j.canlet.2009.04.005 [PubMed] [CrossRef[]
  • Ali E. M., Almagboul A. Z., Khogali S. M., Gergeir U. M. (2012). Antimicrobial activity of Cannabis sativa LSci. Res. J. 3, 61–64. 10.4236/cm.2012.31010 [CrossRef[]
  • Alsaraireh A., Darawad M. W. (2019). Impact of a breast cancer educational program on female University students’ knowledge, attitudes, and practicesJ. Cancer Educ. 34, 315–322. 10.1007/s13187-017-1304-6 [PubMed] [CrossRef[]
  • Andre C. M., Hausman J.-F., Guerriero G. (2016). Cannabis sativa: The plant of the thousand and one moleculesFront. plant Sci. 7, 19. 10.3389/fpls.2016.00019 [PMC free article] [PubMed] [CrossRef[]
  • Antonarakis S. E., Skotko B. G., Rafii M. S., Strydom A., Pape S. E., Bianchi D. W., et al. (2020). Down syndromeJ. Nat. Rev. Dis. Prim. 6, 9–20. 10.1038/s41572-019-0143-7 [PMC free article] [PubMed] [CrossRef[]
  • Appendino G., Gibbons S., Giana A., Pagani A., Grassi G., Stavri M., et al. (2008). Antibacterial cannabinoids from cannabis sativa: A structure− activity studyJ. Nat. Prod. 71, 1427–1430. 10.1021/np8002673 [PubMed] [CrossRef[]
  • Appendino G., Minassi A., Taglialatela-Scafati O. (2014). Recreational drug discovery: Natural products as lead structures for the synthesis of smart drugsNat. Product. Rep. 31, 880–904. 10.1039/c4np00010b [PubMed] [CrossRef[]
  • Arkell T. R., Kevin R. C., Stuart J., Lintzeris N., Haber P. S., Ramaekers J. G., et al. (2019). Detection of Δ9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point‐of‐collection testing devicesDrug Test. analysis J. 11, 1486–1497. 10.1002/dta.2687 [PMC free article] [PubMed] [CrossRef[]
  • Arnarsson A., Kristofersson G. K., Bjarnason T. (2018). Adolescent alcohol and cannabis use in Iceland 1995–2015Drug Alcohol Rev. 37, S49–S57. 10.1111/dar.12587 [PubMed] [CrossRef[]
  • Babiker E. E., Uslu N., Al Juhaimi F., Ahmed I. A. M., Ghafoor K., Özcan M. M., et al. (2021). Effect of roasting on antioxidative properties, polyphenol profile and fatty acids composition of hemp (Cannabis sativa L) seedsLWT 139, 110537. 10.1016/j.lwt.2020.110537 [CrossRef[]
  • Balant M., Gras A., Ruz M., Valles J., Vitales D., Garnatje T. (2021). Traditional uses of Cannabis: An analysis of the CANNUSE databaseJ. Ethnopharmacol. 279, 114362. 10.1016/j.jep.2021.114362 [PubMed] [CrossRef[]
  • Balcke G. U., Bennewitz S., Zabel S., Tissier A. (2014). Isoprenoid and metabolite profiling of plant trichomesMethods Mol. Biol. 1153, 189–202. Plant Isoprenoids. Springer. 10.1007/978-1-4939-0606-2_13 [PubMed] [CrossRef[]
  • Bao Q., Liu H., Fu K., Zhang C., Wang C., Feng Y. (2014). Hemp bast fiber extract with antibacterial activity, preparation method and application of hemp bast fiber extract. USA patent application. []
  • Bar-Or R. L., Kor A., Jaljuli I., Lev-Ran S. (2021). The epidemiology of substance use disorders among the adult Jewish population in IsraelEur. Addict. Res. 27, 362–370. 10.1159/000513776 [PubMed] [CrossRef[]
  • Baral P., Bagul V., Gajbhiye S. (2020). Hemp seed oil for skin care (non-drug cannabis sativa L): A reviewWorld J. Pharm. Res. 9, 2534–2556. []
  • Barrales-Cureño H. J., López-Valdez L. G., Reyes C., Cetina-Alcalá V. M., Vasquez-García I., Diaz-Lira O. F., et al. (2020). Chemical characteristics, therapeutic uses, and legal aspects of the cannabinoids of cannabis sativa: A reviewBraz. Archives Biol. Technol. 63, 1–14. 10.1590/1678-4324-2020190222 [CrossRef[]
  • Barrett M., Gordon D., Evans F. (1985). Isolation from cannabis sativa L. Of cannflavin—a novel inhibitor of prostaglandin productionBiochem. Pharmacol. 34, 2019–2024. 10.1016/0006-2952(85)90325-9 [PubMed] [CrossRef[]
  • Baswan S. M., Klosner A. E., Glynn K., Rajgopal A., Malik K., Yim S., et al. (2020). Therapeutic potential of cannabidiol (CBD) for skin health and disordersClin. Cosmet. investigational dermatology 13, 927–942. 10.2147/CCID.S286411 [PMC free article] [PubMed] [CrossRef[]
  • Baswan S. M., Klosner A. E., Weir C., Salter‐Venzon D., Gellenbeck K. W., Leverett J., et al. (2021). Role of ingestible carotenoids in skin protection: A review of clinical evidencePhotodermatol. Photoimmunol. Photomed. 37, 490–504. 10.1111/phpp.12690 [PubMed] [CrossRef[]
  • Bauer S., Olson J., Cockrill A., Van Hattem M., Miller L., Tauzer M., et al. (2015). Impacts of surface water diversions for marijuana cultivation on aquatic habitat in four northwestern California watershedsPloS one 10, e0120016. 10.1371/journal.pone.0120016 [PMC free article] [PubMed] [CrossRef[]
  • Bautista J. L., Yu S., Tian L. (2021). Flavonoids in Cannabis sativa: Biosynthesis, bioactivities, and biotechnologyACS Omega J. 6, 5119–5123. 10.1021/acsomega.1c00318 [PMC free article] [PubMed] [CrossRef[]
  • Benedicto A., Romayor I., Arteta B. (2017). Role of liver ICAM-1 in metastasisJ. Oncol. Lett. 14, 3883–3892. 10.3892/ol.2017.6700 [PMC free article] [PubMed] [CrossRef[]
  • Bennett J. M., Reeves G., Billman G. E., Sturmberg J. P. (2018). Inflammation–nature’s way to efficiently respond to all types of challenges: Implications for understanding and managing “the epidemic” of chronic diseasesJ Front. Med. 316, 316. 10.3389/fmed.2018.00316 [PMC free article] [PubMed] [CrossRef[]
  • Benowitz N. L., Jones R. T. (1981). Cardiovascular and metabolic considerations in prolonged cannabinoid administration in manJ. Clin. Pharmacol. 21, 214S–223S. 10.1002/j.1552-4604.1981.tb02598.x [PubMed] [CrossRef[]
  • Berman P., Futoran K., Lewitus G. M., Mukha D., Benami M., Shlomi T., et al. (2018). A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in CannabisSci. Rep. 8, 14280. 10.1038/s41598-018-32651-4 [PMC free article] [PubMed] [CrossRef[]
  • Bhattacharyya S., Fusar-Poli P., Borgwardt S., Martin-Santos R., Nosarti C., O’Carroll C., et al. (2009). Modulation of mediotemporal and ventrostriatal function in humans by delta9-tetrahydrocannabinol: A neural basis for the effects of cannabis sativa on learning and psychosisArchives general psychiatry 66, 442–451. 10.1001/archgenpsychiatry.2009.17 [PubMed] [CrossRef[]
  • Bhattacharyya S., Morrison P. D., Fusar-Poli P., Martin-Santos R., Borgwardt S., Winton-Brown T., et al. (2010). Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathologyNeuropsychopharmacology 35, 764–774. 10.1038/npp.2009.184 [PMC free article] [PubMed] [CrossRef[]
  • Blaskovich M. A., Kavanagh A. M., Elliott A. G., Zhang B., Ramu S., Amado M., et al. (2021). The antimicrobial potential of cannabidiolJ. Commun. Biol. 4, 7–18. 10.1038/s42003-020-01530-y [PMC free article] [PubMed] [CrossRef[]
  • Boakye E., Obisesan O. H., Uddin S. I., El-Shahawy O., Dzaye O., Osei A. D., et al. (2021). Cannabis vaping among adults in the United States: Prevalence, trends, and association with high-risk behaviors and adverse respiratory conditionsPrev. Med. 153, 106800. 10.1016/j.ypmed.2021.106800 [PMC free article] [PubMed] [CrossRef[]
  • Bonini S. A., Premoli M., Tambaro S., Kumar A., Maccarinelli G., Memo M., et al. (2018). Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long historyJ. Ethnopharmacol. 227, 300–315. 10.1016/j.jep.2018.09.004 [PubMed] [CrossRef[]
  • Boniotti M. B., Griffith M. E. (2002). “Cross-talk” between cell division cycle and development in plantsPlant Cell 14, 11–16. 10.1105/tpc.140121 [PMC free article] [PubMed] [CrossRef[]
  • Bonn-Miller M. O., Boden M. T., Bucossi M. M., Babson K. A. (2014). Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis usersAm. J. drug alcohol abuse 40, 23–30. 10.3109/00952990.2013.821477 [PubMed] [CrossRef[]
  • Bonn-Miller M. O., Elsohly M. A., Loflin M. J., Chandra S., Vandrey R. (2018). Cannabis and cannabinoid drug development: Evaluating botanical versus single molecule approachesInt. Rev. Psychiatry 30, 277–284. 10.1080/09540261.2018.1474730 [PMC free article] [PubMed] [CrossRef[]
  • Booth J. K., Bohlmann J. (2019). Terpenes in Cannabis sativa–From plant genome to humansJ. Plant Sci. 284, 67–72. 10.1016/j.plantsci.2019.03.022 [PubMed] [CrossRef[]
  • Booth J. (2020). Terpene and isoprenoid biosynthesis in Cannabis sativa. Kelowna: University of British Columbia. []
  • Borah H. J., Bordoloi N. (2020). Chemical constituents of cannabis sativa L(marijuana)Cannabis 18, 1. []
  • Braemer R., Paris M. (1987). Biotransformation of cannabinoids by a cell suspension culture of Cannabis sativa LPlant Cell Rep. 6, 150–152. 10.1007/BF00276675 [PubMed] [CrossRef[]
  • Brennan P., Bogillot O., Greiser E., Chang-Claude J., Wahrendorf J., Cordier S., et al. (2001). The contribution of cigarette smoking to bladder cancer in women (pooled European data)Cancer Causes Control 12, 411–417. 10.1023/a:1011214222810 [PubMed] [CrossRef[]
  • Brewster J. M. (2019). A century of cannabis research in CanadaCan. J. Addict. 10, 6–9. 10.1097/cxa.0000000000000066 [CrossRef[]
  • Brown J. D., Winterstein A. G. (2019). Potential adverse drug events and drug–drug interactions with medical and consumer cannabidiol (CBD) useJ. Clin. Med. 8, 989. 10.3390/jcm8070989 [PMC free article] [PubMed] [CrossRef[]
  • Butsic V., Carah J. K., Baumann M., Stephens C., Brenner J. C. (2018). The emergence of cannabis agriculture frontiers as environmental threatsEnviron. Res. Lett. 13, 124017. 10.1088/1748-9326/aaeade [CrossRef[]
  • Callaway J. C. (2004). Hempseed as a nutritional resource: An overviewEuphytica 140, 65–72. 10.1007/s10681-004-4811-6 [CrossRef[]
  • Canada G. O. (2018). Regulations amending the cannabis regulations (new classes of cannabis): SOR/2019-206Can. Gaz. 153, 3558–3728. []
  • Caplan D. M. (2018). Propagation and root zone management for controlled environment Cannabis production. Guelph: University of Guelph. []
  • Carah J. K., Howard J. K., Thompson S. E., Short Gianotti A. G., Bauer S. D., Carlson S. M., et al. (2015). High time for conservation: Adding the environment to the debate on marijuana liberalizationBioScience 65, 822–829. 10.1093/biosci/biv083 [PMC free article] [PubMed] [CrossRef[]
  • Carlini E. A., Karniol I. G., Renault P., Schuster C. (1974). Effects of marihuana in laboratory animals and in manBr. J. Pharmacol. 50, 299–309. 10.1111/j.1476-5381.1974.tb08576.x [PMC free article] [PubMed] [CrossRef[]
  • Carnevale J. T., Kagan R., Murphy P. J., Esrick J. (2017). A practical framework for regulating for-profit recreational marijuana in US states: Lessons from Colorado and WashingtonInt. J. Drug Policy 42, 71–85. 10.1016/j.drugpo.2017.03.001 [PubMed] [CrossRef[]
  • Caspi A., Moffitt T. E., Cannon M., Mcclay J., Murray R., Harrington H., et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interactionBiol. psychiatry 57, 1117–1127. 10.1016/j.biopsych.2005.01.026 [PubMed] [CrossRef[]
  • Cassano R., Trombino S., Ferrarelli T., Nicoletta F. P., Mauro M. V., Giraldi C., et al. (2013). Hemp fiber (Cannabis sativa L) derivatives with antibacterial and chelating propertiesCellulose 20, 547–557. 10.1007/s10570-012-9804-3 [CrossRef[]
  • Chandra S., Lata H., Khan I. A., Elsohly M. A. (2017). Cannabis sativa L.: Botany and horticulture. Cannabis sativa l.-botany and biotechnology. Cham, Switzerland: Springer. []
  • Chandra S., Lata H., Khan I. A., Elsohly M. A. (2008). Photosynthetic response of Cannabis sativa L. to variations in photosynthetic photon flux densities, temperature and CO 2 conditionsPhysiology Mol. Biol. Plants 14, 299–306. 10.1007/s12298-008-0027-x [PMC free article] [PubMed] [CrossRef[]
  • Chen F., Choi S., Fu C., Nycholat J. (2021). Too high to get it right: The effect of cannabis legalization on the performance of cannabis-related stocksEcon. Analysis Policy 72, 715–734. 10.1016/j.eap.2021.10.001 [CrossRef[]
  • Chouhan S., Guleria S. (2020). Green synthesis of AgNPs using Cannabis sativa leaf extract: Characterization, antibacterial, anti-yeast and α-amylase inhibitory activityMater. Sci. Energy Technol. 3, 536–544. 10.1016/j.mset.2020.05.004 [CrossRef[]
  • Chouvy P.-A. (2019). Cannabis cultivation in the world: Heritages, trends and challenges. Morocco: EchoGéo, 48, 3–10. []
  • Chung M., Benkli B., Hirani S., Le-Short C. (2021). Cannabinoids and cancer pain. Cannabinoids and pain. Cham, Switzerland: Springer. []
  • Clark M. N., Bohm B. A. (1979). Flavonoid variation in cannabis LBotanical J. Linn. Soc. 79, 249–257. 10.1111/j.1095-8339.1979.tb01517.x [CrossRef[]
  • Clarke R. C., Watson D. P. (2002). Botany of natural cannabis medicines. Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential, 3–13. []
  • Clarke R., Merlin M. (2013). Cannabis. Evolution and ethnobotany. LA, USA: University of California Press. []
  • Connor J. P., Stjepanović D., Le Foll B., Hoch E., Budney A. J., Hall W. D. (2021). Cannabis use and cannabis use disorderNat. Rev. Dis. Prim. 7, 16–24. 10.1038/s41572-021-00247-4 [PMC free article] [PubMed] [CrossRef[]
  • Costa B., Trovato A. E., Comelli F., Giagnoni G., Colleoni M. (2007). The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic painEur. J. Pharmacol. 556, 75–83. 10.1016/j.ejphar.2006.11.006 [PubMed] [CrossRef[]
  • Crini G., Lichtfouse E., Chanet G., Morin-Crini N. (2020). Applications of hemp in textiles, paper industry, insulation and building materials, horticulture, animal nutrition, food and beverages, nutraceuticals, cosmetics and hygiene, medicine, agrochemistry, energy production and environment: A reviewEnviron. Chem. Lett. 18, 1451–1476. 10.1007/s10311-020-01029-2 [CrossRef[]
  • Crippa J. A., Guimarães F. S., Campos A. C., Zuardi A. W. (2018). Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new ageFront. Immunol. 9, 2009. 10.3389/fimmu.2018.02009 [PMC free article] [PubMed] [CrossRef[]
  • Cruz J. M., Queirolo R., Boidi M. F. (2016). Determinants of public support for marijuana legalization in Uruguay, the United States, and El SalvadorJ. Drug Issues 46, 308–325. 10.1177/0022042616649005 [CrossRef[]
  • Csakvari A. C., Moisa C., Radu D. G., Olariu L. M., Lupitu A. I., Panda A. O., et al. (2021). Green synthesis, characterization, and antibacterial properties of silver nanoparticles obtained by using diverse varieties of Cannabis sativa leaf extractsMolecules 26, 4041. 10.3390/molecules26134041 [PMC free article] [PubMed] [CrossRef[]
  • Datwyler S. L., Weiblen G. D. (2006). Genetic variation in hemp and marijuana (Cannabis sativa L) according to amplified fragment length polymorphismsJ. Forensic Sci. 51, 371–375. 10.1111/j.1556-4029.2006.00061.x [PubMed] [CrossRef[]
  • Delong G. T., Wolf C. E., Poklis A., Lichtman A. H. (2010). Pharmacological evaluation of the natural constituent of Cannabis sativa cannabichromene and its modulation by Δ9-tetrahydrocannabinolDrug alcohol dependence 112, 126–133. 10.1016/j.drugalcdep.2010.05.019 [PMC free article] [PubMed] [CrossRef[]
  • De Meijer E. P., Bagatta M., Carboni A., Crucitti P., Moliterni V. C., Ranalli P., et al. (2003). The inheritance of chemical phenotype in Cannabis sativa LGenetics 163, 335–346. 10.1093/genetics/163.1.335 [PMC free article] [PubMed] [CrossRef[]
  • De Vita S., Finamore C., Chini M. G., Saviano G., De Felice V., De Marino S., et al. (2022). Phytochemical analysis of the methanolic extract and essential oil from leaves of industrial hemp futura 75 cultivar: Isolation of a new cannabinoid derivative and biological profile using computational approachesPlants 11, 1671. 10.3390/plants11131671 [PMC free article] [PubMed] [CrossRef[]
  • Degenhardt L., Bruno R., Lintzeris N., Hall W., Nielsen S., Larance B., et al. (2015). Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): A cohort studyLancet Psychiatry 2, 314–322. 10.1016/S2215-0366(15)00005-X [PubMed] [CrossRef[]
  • Del Río C., Millán E., García V., Appendino G., Demesa J., Muñoz E. (2018). The endocannabinoid system of the skin. A potential approach for the treatment of skin disordersBiochem. Pharmacol. 157, 122–133. 10.1016/j.bcp.2018.08.022 [PubMed] [CrossRef[]
  • Devane W. A., Dysarz F. R., Johnson M. R., Melvin L. S., Howlett A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brainMol. Pharmacol. 34, 605–613. [PubMed[]
  • Devinsky O., Cilio M. R., Cross H., Fernandez‐Ruiz J., French J., Hill C., et al. (2014). Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disordersEpilepsia 55, 791–802. 10.1111/epi.12631 [PMC free article] [PubMed] [CrossRef[]
  • Dewey W. L. (1986). Cannabinoid pharmacologyPharmacol. Rev. 38, 151–178. [PubMed[]
  • Di Forti M., Morgan C., Dazzan P., Pariante C., Mondelli V., Marques T. R., et al. (2009). High-potency cannabis and the risk of psychosisBr. J. Psychiatry 195, 488–491. 10.1192/bjp.bp.109.064220 [PMC free article] [PubMed] [CrossRef[]
  • Dilley R. J., Morrison W. A. (2014). Vascularisation to improve translational potential of tissue engineering systems for cardiac repairInt. J. Biochem. Cell Biol. 56, 38–46. 10.1016/j.biocel.2014.10.020 [PubMed] [CrossRef[]
  • Dos Santos N. A., Romão W. (2023). Cannabis-a state of the art about the millenary plant: Part IForensic Chem. 32, 100470. 10.1016/j.forc.2023.100470 [CrossRef[]
  • Eggers C., Fujitani M., Kato R., Smid S. (2019). Novel cannabis flavonoid, cannflavin A displays both a hormetic and neuroprotective profile against amyloid β-mediated neurotoxicity in PC12 cells: Comparison with geranylated flavonoids, mimulone and diplaconeBiochem. Pharmacol. 169, 113609. 10.1016/j.bcp.2019.08.011 [PubMed] [CrossRef[]
  • Ellen E., Van Der Sluis M., De H., Rodenburg T. (2018). “Using sensor technologies in animal breeding: Reducing damaging behaviour of animals kept in groups,” in 11th International Conference on Methods and Techniques in Behavioral Research- Measuring behavior 2018, Manchester, UK, 5 June 2018-8 June 2018, 181–182. []
  • Elsohly M. A. (2002). Chemical constituents of cannabis. Binghamton, NY, USA: The Haworth Press. []
  • Elsohly M. A., Slade D. (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoidsLife Sci. 78, 539–548. 10.1016/j.lfs.2005.09.011 [PubMed] [CrossRef[]
  • Elsohly M. A. (2007). Marijuana and the cannabinoids. Totowa, NJ, USA: Springer Science and Business Media. []
  • Elsohly M., Gul W. (2014). Constituents of cannabis sativaHandb. cannabis 3, 187–188. []
  • Elsohly M. A., Radwan M. M., Gul W., Chandra S., Galal A. (2017). “Phytochemistry of cannabis sativa L,” in Phytocannabinoids: unraveling the complex chemistry and pharmacology of cannabis sativa (New York, USA: Springer; ). 1-36. [PubMed[]
  • Erkelens J. L., Hazekamp A. (2014). That which we call Indica, by any other name would smell as sweetCannabinoids 9, 9–15. []
  • Erridge S., Mangal N., Salazar O., Pacchetti B., Sodergren M. H. (2020). Cannflavins–from plant to patient: A scoping reviewFitoterapia 146, 104712. 10.1016/j.fitote.2020.104712 [PubMed] [CrossRef[]
  • Farag S., Kayser O. (2015). Cultivation and breeding of Cannabis sativa L. for preparation of standardized extracts for medicinal purposesJ. Med. aromatic plants world, 165–186. []
  • Farag S., Kayser O. (2017). “The cannabis plant: Botanical aspects,” in Handbook of cannabis and related pathologies (Dortmund, Germany: Elsevier; ). Technical University Dortmund. []
  • Farha M. A., El-Halfawy O. M., Gale R. T., Macnair C. R., Carfrae L. A., Zhang X., et al. (2020). Uncovering the hidden antibiotic potential of cannabisACS Infect. Dis. 6, 338–346. 10.1021/acsinfecdis.9b00419 [PubMed] [CrossRef[]
  • Farinon B., Molinari R., Costantini L., Merendino N. (2020). The seed of industrial hemp (Cannabis sativa L): Nutritional quality and potential functionality for human health and nutritionJ. Nutrients 12, 1935. 10.3390/nu12071935 [PMC free article] [PubMed] [CrossRef[]
  • Fasakin O. W., Oboh G., Ademosun A. O., Lawal A. O. (2022). The modulatory effects of alkaloid extracts of Cannabis sativa, Datura stramonium, Nicotiana tabacum and male Carica papaya on neurotransmitter, neurotrophic and neuroinflammatory systems linked to anxiety and depressionInflammopharmacology 30, 2447–2476. 10.1007/s10787-022-01006-x [PubMed] [CrossRef[]
  • Feder C. L., Cohen O., Shapira A., Katzir I., Peer R., Guberman O., et al. (2021). Fertilization following pollination predominantly decreases phytocannabinoids accumulation and alters the accumulation of terpenoids in cannabis inflorescencesFront. Plant Sci. J. 12, 753847. 10.3389/fpls.2021.753847 [PMC free article] [PubMed] [CrossRef[]
  • Feldman M., Smoum R., Mechoulam R., Steinberg D. (2018). Antimicrobial potential of endocannabinoid and endocannabinoid-like compounds against methicillin-resistant Staphylococcus aureusSci. Rep. 8, 17696. 10.1038/s41598-018-35793-7 [PMC free article] [PubMed] [CrossRef[]
  • Ferrini F., Fraternale D., Donati Zeppa S., Verardo G., Gorassini A., Carrabs V., et al. (2021). Yield, characterization, and possible exploitation of Cannabis sativa L. roots grown under aeroponics cultivationMolecules 26, 4889. 10.3390/molecules26164889 [PMC free article] [PubMed] [CrossRef[]
  • Figuerêdo J. S. D., Santos F. P., Furtado P. V., Andrade T. J., Júnior J. S., Lima N. M., et al. (2022). “Natural products from plants with antimicrobial action,” in Promising antimicrobials from natural products (Cham, Switzerland: Springer; ). []
  • Fischedick J. T. (2017). Identification of terpenoid chemotypes among high (−)-trans-Δ9-tetrahydrocannabinol-producing Cannabis sativa L. cultivarsCannabis cannabinoid Res. 2, 34–47. 10.1089/can.2016.0040 [PMC free article] [PubMed] [CrossRef[]
  • Flicker N. R., Poveda K., Grab H. (2020). The bee community of cannabis sativa and corresponding effects of landscape compositionEnviron. Entomol. 49, 197–202. 10.1093/ee/nvz141 [PubMed] [CrossRef[]
  • Ford T. C., Hayley A. C., Downey L. A., Parrott A. C. (2017). Cannabis: An overview of its adverse acute and chronic effects and its implicationsCurr. drug abuse Rev. 10, 6–18. 10.2174/1874473710666170712113042 [PubMed] [CrossRef[]
  • Fufa B. K. (2019). Anti-bacterial and anti-fungal properties of garlic extract (allium sativum): A reviewInt. J. Microbiol. 28, 1–5. 10.9734/mrji/2019/v28i330133 [CrossRef[]
  • Gabriel M. W., Wengert G. M., Higley J. M., Krogan S., Sargent W., Clifford D. L. (2013). Silent forests. Rodenticides on illegal marijuana crops harm wildlife. [Online], 7. Available at: https://www.iercecology.org/wp-content/uploads/2013/03/Silent_Forests_by_Mourad_W._Gabriel_et_al.TWP_Spring_2013.pdf .
  • Gaffal E., Cron M., Glodde N., Tüting T. (2013). Anti‐inflammatory activity of topical THC in DNFB‐mediated mouse allergic contact dermatitis independent of CB 1 and CB 2 receptorsAllergy 68, 994–1000. 10.1111/all.12183 [PubMed] [CrossRef[]
  • Gage S. H., Hickman M., Zammit S. (2016). Association between cannabis and psychosis: Epidemiologic evidenceJ. Biol. psychiatry 79, 549–556. 10.1016/j.biopsych.2015.08.001 [PubMed] [CrossRef[]
  • Galal A. M., Slade D., Gul W., El-Alfy A. T., Ferreira D., Elsohly M. A. (2009). Naturally occurring and related synthetic cannabinoids and their potential therapeutic applicationsRecent Pat. CNS Drug Discov. Discontin. 4, 112–136. 10.2174/157488909788453031 [PubMed] [CrossRef[]
  • Gaoni Y., Mechoulam R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashishJ. Am. Chem. Soc. 86, 1646–1647. 10.1021/ja01062a046 [CrossRef[]
  • Gaoni Y., Mechoulam R. (1971). The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashishJ. Am. Chem. Soc. 93, 217–224. 10.1021/ja00730a036 [PubMed] [CrossRef[]
  • Garcia-Romeu A., Kersgaard B., Addy P. H. (2016). Clinical applications of hallucinogens: A reviewJ. Exp. Clin. Psychopharmacol. 24, 229–268. 10.1037/pha0000084 [PMC free article] [PubMed] [CrossRef[]
  • Gaston T. E., Szaflarski J. P. (2018). Cannabis for the treatment of epilepsy: An updateJ. Curr. Neurol. Neurosci. Rep. 18, 73–79. 10.1007/s11910-018-0882-y [PubMed] [CrossRef[]
  • Gildea L., Ayariga J. A., Ajayi O. S., Xu J., Villafane R., Samuel-Foo M. (2022). Cannabis sativa CBD extract shows promising antibacterial activity against Salmonella typhimurium and S. NewingtonMolecules 27, 2669. 10.3390/molecules27092669 [PMC free article] [PubMed] [CrossRef[]
  • Gil-Ordóñez A., Martín-Fontecha M., Ortega-Gutiérrez S., López-Rodríguez M. L. (2018). Monoacylglycerol lipase (MAGL) as a promising therapeutic targetJ. Biochem. Pharmacol. 157, 18–32. 10.1016/j.bcp.2018.07.036 [PubMed] [CrossRef[]
  • Głodowska M., Łyszcz M. (2017). Cannabis sativa L. and its antimicrobial properties–A reviewAgron. Sukcesku 11, 77–82. []
  • Gorelick D. A., Heishman S. J. (2006). Methods for clinical research involving cannabis administrationMethods Mol. Med. 123, 235–253. 10.1385/1-59259-999-0:235 [PubMed] [CrossRef[]
  • Grant C. N., Bélanger R. E. (2017). Cannabis and Canada’s children and youthPaediatr. child health 22, 98–102. 10.1093/pch/pxx017 [PMC free article] [PubMed] [CrossRef[]
  • Grotenhermen F. (2004). Clinical pharmacodynamics of cannabinoidsJ. Cannabis Ther. 4, 29–78. 10.1300/j175v04n01_03 [CrossRef[]
  • Gülck T., Møller B. L. (2020). Phytocannabinoids: Origins and biosynthesisTrends plant Sci. 25, 985–1004. 10.1016/j.tplants.2020.05.005 [PubMed] [CrossRef[]
  • Hajizadeh M. (2016). Legalizing and regulating marijuana in Canada: Review of potential economic, social, and health impactsInt. J. health policy Manag. 5, 453–456. 10.15171/ijhpm.2016.63 [PMC free article] [PubMed] [CrossRef[]
  • Haldar S., Gan L., Tay S. L., Ponnalagu S., Henry C. J. (2019). Postprandial glycemic and insulinemic effects of the addition of aqueous extracts of dried corn silk, cumin seed powder or tamarind pulp, in two forms, consumed with high glycemic index riceFoods J. 8, 437. 10.3390/foods8100437 [PMC free article] [PubMed] [CrossRef[]
  • Hall W., Degenhardt L. (2007). Prevalence and correlates of cannabis use in developed and developing countriesCurr. Opin. Psychiatry 20, 393–397. 10.1097/YCO.0b013e32812144cc [PubMed] [CrossRef[]
  • Han Q.-W., Yuan Y.-H., Chen N.-H. (2020). The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson’s diseaseProg. Neuro-Psychopharmacology Biol. Psychiatry 96, 109745. 10.1016/j.pnpbp.2019.109745 [PubMed] [CrossRef[]
  • Hanus L. O., Meyer S. M., Munoz E., Taglialatela-Scafati O., Appendino G. (2016). Phytocannabinoids: A unified critical inventoryNat. Prod. Rep. 33, 1357–1392. 10.1039/c6np00074f [PubMed] [CrossRef[]
  • Hartsel J. A., Boyar K., Pham A., Silver R. J., Makriyannis A. (2019). “Cannabis in veterinary medicine: Cannabinoid therapies for animals,” in Nutraceuticals in veterinary medicine (Cham, Switzerland: Springer; ). []
  • Harvey D. (1976). Characterization of the butyl homologues of delta1-tetrahydrocannabinol, cannabinol and cannabidiol in samples of cannabis by combined gas chromatography and mass spectrometryJ. Pharm. Pharmacol. 28, 280–285. 10.1111/j.2042-7158.1976.tb04153.x [PubMed] [CrossRef[]
  • Harvey D. J., Martin B., Paton W. (1977). Identification of glucuronides as in vivo liver conjugates of seven cannabinoids and some of their hydroxy and acid metabolitesRes. Commun. Chem. Pathology Pharmacol. 16, 265–279. [PubMed[]
  • Hasan K. A. (1975). “Social aspects of the use of cannabis in India,” in Cannabis and culture (Hague, Paris: Mouton Publishers; ), 235–246. []
  • Häuser W., Finn D. P., Kalso E., Krcevski‐Skvarc N., Kress H. G., Morlion B., et al. (2018). European Pain Federation (EFIC) position paper on appropriate use of cannabis‐based medicines and medical cannabis for chronic pain managementEur. J. Pain 22, 1547–1564. 10.1002/ejp.1297 [PubMed] [CrossRef[]
  • Hayakawa K., Mishima K., Hazekawa M., Sano K., Irie K., Orito K., et al. (2008). Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanismBrain Res. 1188, 157–164. 10.1016/j.brainres.2007.09.090 [PubMed] [CrossRef[]
  • Heard K., Marlin M. B., Nappe T., Hoyte C. O. (2017). Common marijuana-related cases encountered in the emergency departmentAm. J. Health-System Pharm. 74, 1904–1908. 10.2146/ajhp160715 [PubMed] [CrossRef[]
  • Hellmich M. R., Szabo C. (2015). Hydrogen sulfide and cancerChem. Biochem. Pharmacol. Hydrogen Sulfide 230, 233–241. 10.1007/978-3-319-18144-8_12 [PMC free article] [PubMed] [CrossRef[]
  • Hindocha C., Brose L. S., Walsh H., Cheeseman H. (2021). Cannabis use and co-use in tobacco smokers and non-smokers: Prevalence and associations with mental health in a cross-sectional, nationally representative sample of adults in great britain, 2020J. Addict. 116, 2209–2219. 10.1111/add.15381 [PubMed] [CrossRef[]
  • Holland J. (2010). The pot book: A complete guide to cannabis. Toronto, Canada: Simon and Schuster. []
  • Howlett A., Barth F., Bonner T., Cabral G., Casellas P., Devane W., et al. (2002). International union of pharmacology. XXVII. Classification of cannabinoid receptorsPharmacol. Rev. 54, 161–202. 10.1124/pr.54.2.161 [PubMed] [CrossRef[]
  • Hryhorowicz S., Kaczmarek-Ryś M., Zielińska A., Scott R. J., Słomski R., Pławski A. (2021). Endocannabinoid system as a promising therapeutic target in inflammatory bowel disease–A systematic reviewJ Front. Immunol. 12, 790803. 10.3389/fimmu.2021.790803 [PMC free article] [PubMed] [CrossRef[]
  • Iannotti F. A., Di Marzo V., Petrosino S. (2016). Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disordersJ Prog. lipid Res. 62, 107–128. 10.1016/j.plipres.2016.02.002 [PubMed] [CrossRef[]
  • Iannotti F. A., De Maio F., Panza E., Appendino G., Taglialatela-Scafati O., De Petrocellis L., et al. (2020). Identification and characterization of cannabimovone, a cannabinoid from Cannabis sativa, as a novel PPARγ agonist via a combined computational and functional studyMolecules 25, 1119. 10.3390/molecules25051119 [PMC free article] [PubMed] [CrossRef[]
  • Iber B. T., Kasan N. A., Torsabo D., Omuwa J. W. (2022). A review of various sources of chitin and chitosan in natureJ. Renew. Mater. 10, 1097–1123. 10.32604/jrm.2022.018142 [CrossRef[]
  • Iftikhar A., Zafar U., Ahmed W., Shabbir M. A., Sameen A., Sahar A., et al. (2021). Applications of cannabis sativa L. In food and its therapeutic potential: From a prohibited drug to a nutritional supplementMolecules 26, 7699. 10.3390/molecules26247699 [PMC free article] [PubMed] [CrossRef[]
  • Ilgen M. A., Bohnert K., Kleinberg F., Jannausch M., Bohnert A. S., Walton M., et al. (2013). Characteristics of adults seeking medical marijuana certificationDrug alcohol dependence 132, 654–659. 10.1016/j.drugalcdep.2013.04.019 [PubMed] [CrossRef[]
  • Irakli M., Tsaliki E., Kalivas A., Kleisiaris F., Sarrou E., Cook C. M. (2019). Effect οf genotype and growing year on the nutritional, phytochemical, and antioxidant properties of industrial hemp (Cannabis sativa L) seedsAntioxidants 8, 491. 10.3390/antiox8100491 [PMC free article] [PubMed] [CrossRef[]
  • Iseppi R., Brighenti V., Licata M., Lambertini A., Sabia C., Messi P., et al. (2019). Chemical characterization and evaluation of the antibacterial activity of essential oils from fibre-type Cannabis sativa L(Hemp)Molecules 24, 2302. 10.3390/molecules24122302 [PMC free article] [PubMed] [CrossRef[]
  • Iwamura H., Suzuki H., Ueda Y., Kaya T., Inaba T. (2001). In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptorJ. Pharmacol. Exp. Ther. 296, 420–425. [PubMed[]
  • Jagannathan R. (2020). Identification of psychoactive metabolites from Cannabis sativa, its smoke, and other phytocannabinoids using machine learning and multivariate methodsACS omega 5, 281–295. 10.1021/acsomega.9b02663 [PMC free article] [PubMed] [CrossRef[]
  • Jin D., Dai K., Xie Z., Chen J. (2020). Secondary metabolites profiled in cannabis inflorescences, leaves, stem barks, and roots for medicinal purposesSci. Rep. 10, 3309–3314. 10.1038/s41598-020-60172-6 [PMC free article] [PubMed] [CrossRef[]
  • Johnson R. (2014). Hemp as an agricultural commodity. Washington: Library of Congress Washington DC Congressional Research Service, 34. []
  • Jurgoński A., Opyd P. M., Fotschki B. (2020). Effects of native or partially defatted hemp seeds on hindgut function, antioxidant status and lipid metabolism in diet-induced obese ratsJ. Funct. Foods 72, 104071. 10.1016/j.jff.2020.104071 [CrossRef[]
  • Kalant H. (2010). Drug classification: Science, politics, both or neither? Addiction 105, 1146–1149. 10.1111/j.1360-0443.2009.02830.x [PubMed] [CrossRef[]
  • Kanabus J., Bryła M., Roszko M., Modrzewska M., Pierzgalski A. (2021). Cannabinoids—characteristics and potential for use in food productionMolecules 26, 6723. 10.3390/molecules26216723 [PMC free article] [PubMed] [CrossRef[]
  • Kaplan J. S., Stella N., Catterall W. A., Westenbroek R. E. (2017). Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndromeJ Proc. Natl. Acad. Sci. 114, 11229–11234. 10.1073/pnas.1711351114 [PMC free article] [PubMed] [CrossRef[]
  • Karas J. A., Wong L. J., Paulin O. K., Mazeh A. C., Hussein M. H., Li J., et al. (2020). The antimicrobial activity of cannabinoidsJ. Antibiotics 9, 406. 10.3390/antibiotics9070406 [PMC free article] [PubMed] [CrossRef[]
  • Karbakhsh M., Smith J., Pike I. (2018). Where does the high road lead? Potential implications of cannabis legalization for pediatric injuries in CanadaCan. J. public health 109, 752–755. 10.17269/s41997-018-0137-3 [PMC free article] [PubMed] [CrossRef[]
  • Karniol I., Carlini E. (1973). Comparative studies in man and in laboratory animals on▵ 8-and▵ 9-trans-TetrahydrocannabinolPharmacology 9, 115–126. 10.1159/000136375 [PubMed] [CrossRef[]
  • Karwad M. A., Couch D. G., Theophilidou E., Sarmad S., Barrett D. A., Larvin M., et al. (2017). The role of CB1 in intestinal permeability and inflammationJ FASEB J. 31, 3267–3277. 10.1096/fj.201601346R [PubMed] [CrossRef[]
  • Khan S., Al Baradie R. (2012). Epileptic encephalopathies: An overviewEpilepsy Res. Treat. 2012, 403592. 10.1155/2012/403592 [PMC free article] [PubMed] [CrossRef[]
  • Kilaru A., Chapman K. D. (2020). The endocannabinoid systemJ Essays Biochem. 64, 485–499. 10.1042/EBC20190086 [PubMed] [CrossRef[]
  • Kilmer B., Maccoun R. J. (2017). How medical marijuana smoothed the transition to marijuana legalization in the United StatesAnnu. Rev. Law Soc. Sci. 13, 181–202. 10.1146/annurev-lawsocsci-110615-084851 [PMC free article] [PubMed] [CrossRef[]
  • Kinghorn A. D., Falk H., Gibbons S., Kobayashi J. I. (2017). Phytocannabinoids. Cham, Switzerland: Springer. []
  • Kitchen C., Kabba J. A., Fang Y. (2022). Status and impacts of recreational and medicinal cannabis policies in Africa: A systematic review and thematic analysis of published and “gray” literatureCannabis cannabinoid Res. 7, 239–261. 10.1089/can.2021.0110 [PMC free article] [PubMed] [CrossRef[]
  • Ko G. D., Bober S. L., Mindra S., Moreau J. M. (2016). Medical cannabis–the Canadian perspectiveJ. pain Res. 9, 735–744. 10.2147/JPR.S98182 [PMC free article] [PubMed] [CrossRef[]
  • Kocatürk R. R., Zelka F. Z., Özcan Ö. Ö., Canbolat F. (2021). “Antioxidant effects of peptides,” in Synthetic peptide vaccine models (Boca Raton, FL, USA: CRC Press; ). []
  • Kopustinskiene D. M., Masteikova R., Lazauskas R., Bernatoniene J. (2022). Cannabis sativa L. Bioactive compounds and their protective role in oxidative stress and inflammationAntioxidants 11, 660. 10.3390/antiox11040660 [PMC free article] [PubMed] [CrossRef[]
  • Kriese U., Schumann E., Weber W., Beyer M., Brühl L., Matthäus B. (2004). Oil content, tocopherol composition and fatty acid patterns of the seeds of 51 Cannabis sativa L. genotypesEuphytica 137, 339–351. 10.1023/b:euph.0000040473.23941.76 [CrossRef[]
  • Krist S. (2020). Vegetable fats and oils. Cham, Switzerland: Springer. []
  • Kumar P., Mahato D. K., Kamle M., Borah R., Sharma B., Pandhi S., et al. (2021). Pharmacological properties, therapeutic potential, and legal status of Cannabis sativa L.: An overviewPhytotherapy Res. 35, 6010–6029. 10.1002/ptr.7213 [PubMed] [CrossRef[]
  • Kumar S., Pandey A. K. (2013). Chemistry and biological activities of flavonoids: An overviewSci. world J. 2013, 162750. 10.1155/2013/162750 [PMC free article] [PubMed] [CrossRef[]
  • Kuppuram G. (2022). The nutritional and therapeutical value of Cannabis SattivaJ. Assoc. Res. 27, 18–23. []
  • Laezza C., Pagano C., Navarra G., Pastorino O., Proto M. C., Fiore D., et al. (2020). The endocannabinoid system: A target for cancer treatmentInt. J. Mol. Sci. 21, 747. 10.3390/ijms21030747 [PMC free article] [PubMed] [CrossRef[]
  • Laidlaw A. M. (2016). Control and detection of enterohaemorrhagic Escherichia coli. Alberta: University of Alberta. []
  • Lakhan S. E., Rowland M. (2009). Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: A systematic reviewBMC Neurol. 9, 1–6. 10.1186/1471-2377-9-59 [PMC free article] [PubMed] [CrossRef[]
  • Larkin P. J., JR, Madras B. K. (2019). Opioids, overdoses, and cannabis: Is marijuana an effective therapeutic response to the opioid abuse epidemicGeo. JL Pub. Pol’y 17, 555. []
  • Lata H., Chandra S., Techen N., Khan I. A., Elsohly M. A. (2016). In vitro mass propagation of cannabis sativa L.: A protocol refinement using novel aromatic cytokinin meta-topolin and the assessment of eco-physiological, biochemical and genetic fidelity of micropropagated plantsJ. Appl. Res. Med. Aromatic Plants 3, 18–26. 10.1016/j.jarmap.2015.12.001 [CrossRef[]
  • Lattanzi S., Zaccara G., Russo E., La Neve A., Lodi M. A. M., Striano P. (2021). Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndromeExpert Rev. Neurother. 21, 99–110. 10.1080/14737175.2021.1834383 [PubMed] [CrossRef[]
  • Lau W. M., Teng E., Huang K. K., Tan J. W., Das K., Zang Z., et al. (2018). Acquired resistance to FGFR inhibitor in diffuse-type gastric cancer through an AKT-independent PKC-mediated phosphorylation of GSK3βJ. Mol. Cancer Ther. 17, 232–242. 10.1158/1535-7163.MCT-17-0367 [PubMed] [CrossRef[]
  • Le Boisselier R., Alexandre J., Lelong-Boulouard V., Debruyne D. (2017). Focus on cannabinoids and synthetic cannabinoidsClin. Pharmacol. Ther. 101, 220–229. 10.1002/cpt.563 [PubMed] [CrossRef[]
  • Leos-Toro C. (2019). Health warnings, cannabis marketing and perceptions among youth and young adults in Canada[]
  • Li C.-R., Yang L.-X., Guo Z.-F., Yang H., Zhang Y., Wang Y.-M., et al. (2022). LC-MS-based untargeted metabolomics reveals chemical differences of Cannabis leaves from different regions of ChinaIndustrial Crops Prod. 176, 114411. 10.1016/j.indcrop.2021.114411 [CrossRef[]
  • Li H.-L. (1974). An archaeological and historical account of cannabis in ChinaEcon. Bot. 28, 437–448. 10.1007/bf02862859 [CrossRef[]
  • Liktor-Busa E., Keresztes A., Lavigne J., Streicher J. M., Largent-Milnes T. M. (2021). Analgesic potential of terpenes derived from cannabis sativaJ. Pharmacol. Rev. 73, 98–126. 10.1124/pharmrev.120.000046 [PubMed] [CrossRef[]
  • Lin A., O’Connor M., Behnam R., Hatef C., Milanaik R. (2022). Edible marijuana products and potential risks for pediatric populationsCurr. Opin. Pediatr. 34, 279–287. 10.1097/MOP.0000000000001132 [PubMed] [CrossRef[]
  • Lindblom E. N. (2019). How FDA could use its existing authorities to make state legalization of cannabis more safe and effectiveFood and Drug LJ 74, 191. []
  • Lindley J. (2011). “Flora medica: A botanical account of all the more important plants used in medicine,” in Different parts of the world (Cambridge, UK: Cambridge University Press; ). []
  • Linnaeus C. (1753). Species Plantarum, vol. 1. Stockholm: Laurentius Salvius, 150. []
  • Lohar V., Rathore A. S. (2013). Cannabinoids: Pharmacological profile of promising moleculesPhytopharm. J. 4, 41–52. []
  • López‐Ruiz R., Marín‐Sáez J., Garrido Frenich A., Romero‐González R. (2022). Recent applications of chromatography for analysis of contaminants in cannabis products: A reviewPest Manag. Sci. 78, 19–29. 10.1002/ps.6599 [PubMed] [CrossRef[]
  • Lowe H., Steele B., Bryant J., Toyang N., Ngwa W. (2021). Non-cannabinoid metabolites of Cannabis sativa L. with therapeutic potentialPlants J. 10, 400. 10.3390/plants10020400 [PMC free article] [PubMed] [CrossRef[]
  • Macdonald R., Rotermann M. (2017). Experimental estimates of cannabis consumption in Canada, 1960 to 2015 [Online]. Statistics Canada= Statistique Canada. Available at: https://www150.statcan.gc.ca/n1/pub/11-626-x/11-626-x2017077-eng.htm (Accessed December 20, 2022).
  • Mander L., Liu H.-W. (2010). Comprehensive natural products II: Chemistry and biology. Oxford, U.K: Elsevier. []
  • Manske R. H. F., Holmes H. L. (2014). The alkaloids: Chemistry and physiology. Guelph, Ontario: Elsevier. []
  • Maroon J., Bost J. (2018). Review of the neurological benefits of phytocannabinoidsSurg. Neurol. Int. 9, 91. 10.4103/sni.sni_45_18 [PMC free article] [PubMed] [CrossRef[]
  • Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNANature 346, 561–564. 10.1038/346561a0 [PubMed] [CrossRef[]
  • Mcpartland J., Di Marzo V., De Petrocellis L., Mercer A., Glass M. (2001). Cannabinoid receptors are absent in insectsJ. Comp. Neurology 436, 423–429. 10.1002/cne.1078 [PubMed] [CrossRef[]
  • Mcpartland J. M., Mckernan K. J. (2017). “Contaminants of concern in cannabis: Microbes, heavy metals and pesticides,” in Cannabis sativa L.-Botany and biotechnology (Cham, Switzerland: Springer; ). []
  • Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N. E., Schatz A. R., et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptorsBiochem. Pharmacol. 50, 83–90. 10.1016/0006-2952(95)00109-d [PubMed] [CrossRef[]
  • Mechoulam R., Shvo Y. (1963). Hashish—I: The structure of cannabidiolTetrahedron 19, 2073–2078. 10.1016/0040-4020(63)85022-x [PubMed] [CrossRef[]
  • Mechoulam R., Hanuš L. R. (2000). A historical overview of chemical research on cannabinoidsChem. Phys. Lipids 108, 1–13. 10.1016/s0009-3084(00)00184-5 [PubMed] [CrossRef[]
  • Michailidis D., Angelis A., Nikolaou P. E., Mitakou S., Skaltsounis A. L. (2021). Exploitation of vitis vinifera, foeniculum vulgare, cannabis sativa and punica granatum by-product seeds as dermo-cosmetic agentsMolecules 26, 731. 10.3390/molecules26030731 [PMC free article] [PubMed] [CrossRef[]
  • Mihoc M., Pop G., Alexa E., Radulov I. (2012). Nutritive quality of Romanian hemp varieties (Cannabis sativa L) with special focus on oil and metal contents of seedsChem. Central J. 6, 1–12. [PMC free article] [PubMed[]
  • Minelli A. (2015). “Morphological misfits and the architecture of development,” in Macroevolution (Cham, Switzerland: Springer; ), 329–343. []
  • Mnekin L., Ripoll L. (2021). Topical use of cannabis sativa L. BiochemicalsCosmetics 8, 85. 10.3390/cosmetics8030085 [CrossRef[]
  • Moliterni V. M. C., Pojić M., Tiwari B. (2022). “Industrial hemp by-product valorization,” in Industrial hemp (Massachusetts, USA: Elsevier; ). []
  • Mölleken H., Theimer R. R. (1997). Survey of minor fatty acids in Cannabis sativa L. fruits of various originsJ. Int. Hemp Assoc. 4, 13–17. []
  • Morimoto S., Komatsu K., Taura F., Shoyama Y. (1998). Purification and characterization of cannabichromenic acid synthase from Cannabis sativaPhytochemistry 49, 1525–1529. 10.1016/s0031-9422(98)00278-7 [PubMed] [CrossRef[]
  • Moyle P. B. (2002). Inland fishes of California: Revised and expanded. LA, USA: Univ of California Press. []
  • Mrowka P., Glodkowska-Mrowka E. (2020). PPARγ agonists in combination cancer therapiesJ. Curr. Cancer Drug Targets 20, 197–215. 10.2174/1568009619666191209102015 [PubMed] [CrossRef[]
  • Mustafa G., Arif R., Atta A., Sharif S., Jamil A. (2017). Bioactive compounds from medicinal plants and their importance in drug discovery in PakistanMatrix Sci. Pharma 1, 17–26. 10.26480/msp.01.2017.17.26 [CrossRef[]
  • Nahhas A. F., Abdel-Malek Z. A., Kohli I., Braunberger T. L., Lim H. W., Hamzavi I. H. (2019). The potential role of antioxidants in mitigating skin hyperpigmentation resulting from ultraviolet and visible light‐induced oxidative stressPhotodermatol. Photoimmunol. Photomed. 35, 420–428. 10.1111/phpp.12423 [PubMed] [CrossRef[]
  • Nallathambi R., Mazuz M., Ion A., Selvaraj G., Weininger S., Fridlender M., et al. (2017). Anti-inflammatory activity in colon models is derived from δ9-tetrahydrocannabinolic acid that interacts with additional compounds in cannabis extractsCannabis cannabinoid Res. 2, 167–182. 10.1089/can.2017.0027 [PMC free article] [PubMed] [CrossRef[]
  • Naveed M., Khan T. A., Ali I., Hassan A., Ali H., Ud Z., et al. (2014). In vitro antibacterial activity of Cannabis sativa leaf extracts to some selective pathogenicbacterial strainsInt. J. Biosci. 4, 65–70. []
  • Novak J., Zitterl-Eglseer K., Deans S. G., Franz C. M. (2001). Essential oils of different cultivars of Cannabis sativa L. and their antimicrobial activityFlavour Fragr. J. 16, 259–262. 10.1002/ffj.993 [CrossRef[]
  • Nyland C. R., Moyer D. C. (2022). Regulating for safety: Cannabidiol dose in food: A reviewJ. food Prot. 85, 1355–1369. 10.4315/JFP-21-374 [PubMed] [CrossRef[]
  • Oberbarnscheidt T., Miller N. S. (2020). The impact of cannabidiol on psychiatric and medical conditionsJ. Clin. Med. Res. 12, 393–403. 10.14740/jocmr4159 [PMC free article] [PubMed] [CrossRef[]
  • Odieka A. E., Obuzor G. U., Oyedeji O. O., Gondwe M., Hosu Y. S., Oyedeji A. O. (2022). The medicinal natural products of cannabis sativa Linn.: A reviewMolecules 27, 1689. 10.3390/molecules27051689 [PMC free article] [PubMed] [CrossRef[]
  • Pamplona F. A., Da Silva L. R., Coan A. C. (2018). Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: Observational data meta-analysisFront. neurology 9, 759. 10.3389/fneur.2018.00759 [PMC free article] [PubMed] [CrossRef[]
  • Pate D. W. (1994). Chemical ecology of cannabisJ. Int. Hemp Assoc. 2, 32–37. []
  • Pavlovic R., Panseri S., Giupponi L., Leoni V., Citti C., Cattaneo C., et al. (2019). Phytochemical and ecological analysis of two varieties of hemp (Cannabis sativa L) grown in a mountain environment of Italian AlpsFront. Plant Sci. 10, 1265. 10.3389/fpls.2019.01265 [PMC free article] [PubMed] [CrossRef[]
  • Pellati F., Borgonetti V., Brighenti V., Biagi M., Benvenuti S., Corsi L. (2018). Cannabis sativa L. And nonpsychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancerJ. BioMed Res. Int. 2018, 1691428. 10.1155/2018/1691428 [PMC free article] [PubMed] [CrossRef[]
  • Peng H., Shahidi F. (2021). Cannabis and cannabis edibles: A reviewJ. Agric. Food Chem. 69, 1751–1774. 10.1021/acs.jafc.0c07472 [PubMed] [CrossRef[]
  • Perucca E. (2017). Cannabinoids in the treatment of epilepsy: Hard evidence at last? J. epilepsy Res. 7, 61–76. 10.14581/jer.17012 [PMC free article] [PubMed] [CrossRef[]
  • Piccolella S., Crescente G., Formato M., Pacifico S. (2020). A cup of hemp coffee by moka pot from Southern Italy: An UHPLC-HRMS investigationFoods 9, 1123. 10.3390/foods9081123 [PMC free article] [PubMed] [CrossRef[]
  • Piomelli D., Russo E. B. (2016). The cannabis sativa versus cannabis indica debate: An interview with ethan Russo, MDCannabis cannabinoid Res. 1, 44–46. 10.1089/can.2015.29003.ebr [PMC free article] [PubMed] [CrossRef[]
  • Pollastro F., Minassi A., Fresu L. G. (2018). Cannabis phenolics and their bioactivitiesCurr. Med. Chem. 25, 1160–1185. 10.2174/0929867324666170810164636 [PubMed] [CrossRef[]
  • Poewe W., Seppi K., Tanner C. M., Halliday G. M., Brundin P., Volkmann J., et al. (2017). Parkinson diseaseNat. Rev. Dis. Prim. 3, 17013–17021. 10.1038/nrdp.2017.13 [PubMed] [CrossRef[]
  • Pollio A. (2016). The name of cannabis: A short guide for nonbotanistsCannabis cannabinoid Res. 1, 234–238. 10.1089/can.2016.0027 [PMC free article] [PubMed] [CrossRef[]
  • Polson G., Chung M., Hirani S., Le-Short C. (2021). “Cannabis drug interactions,” in Cannabinoids and pain (Cham, Switzerland: Springer; ). []
  • Popescu-Spineni D. M., Moldoveneau A. C., Armean P., Ionescu-Tirgoviste C., Militaru C., Munteanu A. M. (2021). Antimicobial effect of cannabis sativa LRev. Roum. Chim J. 66, 417–422. []
  • Potter D. J. (2014). A review of the cultivation and processing of cannabis (Cannabis sativa L) for production of prescription medicines in the UKDrug Test. analysis 6, 31–38. 10.1002/dta.1531 [PubMed] [CrossRef[]
  • Radwan M. M., Wanas A. S., Chandra S., Elsohly M. A. (2017). Natural cannabinoids of cannabis and methods of analysis. Cannabis sativa l.-botany and biotechnology. New York, USA: Springer. []
  • Radwan M. M., Chandra S., Gul S., Elsohly M. A. (2021). Cannabinoids, phenolics, terpenes and alkaloids of cannabisMolecules 26, 2774. 10.3390/molecules26092774 [PMC free article] [PubMed] [CrossRef[]
  • Ramantani G., Kadish N. E., Strobl K., Brandt A., Stathi A., Mayer H., et al. (2013). Seizure and cognitive outcomes of epilepsy surgery in infancy and early childhoodEur. J. Paediatr. neurology 17, 498–506. 10.1016/j.ejpn.2013.03.009 [PubMed] [CrossRef[]
  • Ramirez C. L., Fanovich M. A., Churio M. S. (2019). Cannabinoids: Extraction methods, analysis, and physicochemical characterizationJ. Stud. Nat. Prod. Chem. 61, 143–173. 10.1016/B978-0-444-64183-0.00004-X [CrossRef[]
  • Rana A., Musto A. E. (2018). The role of inflammation in the development of epilepsyJ. Neuroinflammation 15, 1–12. 10.1186/s12974-018-1192-7 [PMC free article] [PubMed] [CrossRef[]
  • Ranieri R., Marasco D., Bifulco M., M Malfitano A. (2015). Phytocannabinoids and cannabimimetic drugs: Recent patents in central nervous system disordersJ. Recent Pat. CNS Drug Discov. 10, 157–177. 10.2174/1574889810666160517123938 [PubMed] [CrossRef[]
  • Rasera G. B., Ohara A., De Castro R. J. S. (2021). Innovative and emerging applications of cannabis in food and beverage products: From an illicit drug to a potential ingredient for health promotionTrends Food Sci. Technol. 115, 31–41. 10.1016/j.tifs.2021.06.035 [CrossRef[]
  • Rasool U. (2018). Safety and efficacy of hemp products in broiler production. Winnipeg: University of Manitoba. []
  • Rather I. A., Koh W. Y., Paek W. K., Lim J. (2017). The sources of chemical contaminants in food and their health implicationsFront. Pharmacol. 8, 830. 10.3389/fphar.2017.00830 [PMC free article] [PubMed] [CrossRef[]
  • Ren G., Zhang X., Li Y., Ridout K., Serrano-Serrano M. L., Yang Y., et al. (2021). Large-scale whole-genome resequencing unravels the domestication history of Cannabis sativaSci. Adv. 7, eabg2286. 10.1126/sciadv.abg2286 [PMC free article] [PubMed] [CrossRef[]
  • Rhee M.-H., Vogel Z., Barg J., Bayewitch M., Levy R., Hanuš L., et al. (1997). Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylylcyclaseJ. Med. Chem. 40, 3228–3233. 10.1021/jm970126f [PubMed] [CrossRef[]
  • Ribeiro A. M., Estevinho B. N., Rocha F. J. F., Technology B. (2021). Preparation and incorporation of functional ingredients in edible films and coatingsFood bioproc. Tech. 14, 209–231. 10.1007/s11947-020-02528-4 [CrossRef[]
  • Riboulet-Zemouli K., Krawitz M. A. (2022). WHO’s first scientific review of medicinal cannabis: From global struggle to patient implicationsJ. Drugs, Habits Soc. Policy 23 (1), 5–21. 10.1108/dhs-11-2021-0060 [CrossRef[]
  • Richards J. R., Blohm E., Toles K. A., Jarman A. F., Ely D. F., Elder J. W. (2020). The association of cannabis use and cardiac dysrhythmias: A systematic reviewClin. Toxicol. 58, 861–869. 10.1080/15563650.2020.1743847 [PubMed] [CrossRef[]
  • Romano L., Hazekamp A. (2019). An overview of galenic preparation methods for medicinal cannabisCurr. Bioact. Compd. 15, 174–195. 10.2174/1573407214666180612080412 [CrossRef[]
  • Romero P., Peris A., Vergara K., Matus J. T. (2020). Comprehending and improving cannabis specialized metabolism in the systems biology eraPlant Sci. 298, 110571. 10.1016/j.plantsci.2020.110571 [PubMed] [CrossRef[]
  • Ross S. A., Elsohly H. N., Elkashoury E. A., Elsohly M. A. (1996). Fatty acids of cannabis seedsPhytochem. Anal. 7, 279–283. 10.1002/(sici)1099-1565(199611)7:6<279::aid-pca322>3.0.co;2-p [CrossRef[]
  • Ross S., Elsohly M. (1997). CBN and∆ 9-THC concentration ratio as an indicator of the age of stored marijuana samplesBull. Narcotics 49, 139. []
  • Ross S. A., Elsohly M. A., Sultana G. N., Mehmedic Z., Hossain C. F., Chandra S. (2005). Flavonoid glycosides and cannabinoids from the pollen of Cannabis sativa LInt. J. Plant Chem. Biochem. Tech. 16, 45–48. 10.1002/pca.809 [PubMed] [CrossRef[]
  • Russia I. K., Sweden G. L., Pakistan Z. A., Argentina L. B. F., India S. J. B., Mexico M. S., et al. (2015). Irritable bowel syndrome: A global perspectiveJ. Update[]
  • Russo E. B., Marcu J. (2017). Cannabis pharmacology: The usual suspects and a few promising leadsAdv. Pharmacol. 80, 67–134. 10.1016/bs.apha.2017.03.004 [PubMed] [CrossRef[]
  • Russo E. B. (2014). The pharmacological history of CannabisHandb. cannabis, 23–43. 10.1093/acprof:oso/9780199662685.003.0002 [CrossRef[]
  • Russo E. B. (2016). “The solution to the medicinal cannabis problem,” in Ethical issues in chronic pain management (Boca Raton: CRC Press; ). []
  • Ryz N. R., Remillard D. J., Russo E. B. (2017). Cannabis roots: A traditional therapy with future potential for treating inflammation and painCannabis cannabinoid Res. 2, 210–216. 10.1089/can.2017.0028 [PMC free article] [PubMed] [CrossRef[]
  • Sakarin S., Meesiripan N., Sangrajrang S., Suwanpidokkul N., Prayakprom P., Bodhibukkana C., et al. (2022). Antitumor effects of cannabinoids in human pancreatic ductal adenocarcinoma cell line (Capan-2)-Derived xenograft mouse modelJ Front. Veterinary Sci. 9, 867575. 10.3389/fvets.2022.867575 [PMC free article] [PubMed] [CrossRef[]
  • Salamat J. M., Ledbetter E. L., Abbott K. L., Thungrat K., Flannery P. C., Huang C.-C. J., et al. (2022). “Cannabinoids in cancer: Cross-talk between cannabinoids and miRNAs,” in Cannabis/marijuana for healthcare (Cham, Switzerland: Springer; ). []
  • Saloner A., Sacks M. M., Bernstein N. (2019). Response of medical cannabis (Cannabis sativa L) genotypes to K supply under long photoperiodFront. Plant Sci. 10, 1369. 10.3389/fpls.2019.01369 [PMC free article] [PubMed] [CrossRef[]
  • Saqib U., Sarkar S., Baig M. (2017). Inflammation and its disease consequencesJ. Immun. Res. 4, 1027. []
  • Sarris J., Sinclair J., Karamacoska D., Davidson M., Firth J. (2020). Medicinal cannabis for psychiatric disorders: A clinically-focused systematic reviewJ. BMC psychiatry 20, 24–14. 10.1186/s12888-019-2409-8 [PMC free article] [PubMed] [CrossRef[]
  • Sarvet A. L., Wall M. M., Fink D. S., Greene E., Le A., Boustead A. E., et al. (2018). Medical marijuana laws and adolescent marijuana use in the United States: A systematic review and meta-analysisAddiction 113, 1003–1016. 10.1111/add.14136 [PMC free article] [PubMed] [CrossRef[]
  • Sauerbier A., Jenner P., Todorova A., Chaudhuri K. R. (2016). Non motor subtypes and Parkinson’s diseaseJ. Park. Relat. Disord. 22, S41–S46. 10.1016/j.parkreldis.2015.09.027 [PubMed] [CrossRef[]
  • Sawicka B., Skiba D., Umachandran K., Dickson A. (2021). “Alternative and new plants,” in Preparation of phytopharmaceuticals for the management of disorders (London, UK: Elsevier; ). []
  • Schauer G. L., King B. A., Bunnell R. E., Promoff G., Mcafee T. A. (2016). Toking, vaping, and eating for health or fun: Marijuana use patterns in adults, US, 2014Am. J. Prev. Med. 50, 1–8. 10.1016/j.amepre.2015.05.027 [PubMed] [CrossRef[]
  • Schettino L., Prieto M., Benedé J. L., Chisvert A., Salvador A. (2021). A rapid and sensitive method for the determination of cannabidiol in cosmetic products by liquid chromatography–tandem mass spectrometryCosmetics 8, 30. 10.3390/cosmetics8020030 [CrossRef[]
  • Schlenker W., Hanemann W. M., Fisher A. C. (2007). Water availability, degree days, and the potential impact of climate change on irrigated agriculture in CaliforniaClim. Change 81, 19–38. 10.1007/s10584-005-9008-z [CrossRef[]
  • Schultes R. E., Klein W. M., Plowman T., Lockwood T. E. (1975). Cannabis: An example of taxonomic neglectCannabis Cult., 21–38. 10.1515/9783110812060.21 [CrossRef[]
  • Seltenrich N. (2019). Cannabis contaminants: Regulating solvents, microbes, and metals in legal weedEnviron. Health Perspect. 127 (8), 82001. 10.1289/EHP5785 [PMC free article] [PubMed] [CrossRef[]
  • Seltzer E. S., Watters A. K., Mackenzie D., JR, Granat L. M., Zhang D. (2020). Cannabidiol (CBD) as a promising anti-cancer drugJ. Cancers 12, 3203. 10.3390/cancers12113203 [PMC free article] [PubMed] [CrossRef[]
  • Sergi D., Boulestin H., Campbell F. M., Williams L. M. (2021). The role of dietary advanced glycation end products in metabolic dysfunctionJ Mol. Nutr. Food Res. 65, 1900934. 10.1002/mnfr.201900934 [PubMed] [CrossRef[]
  • Sharma G. (1979). Significance of eco-chemical studies in cannabis [hemp (drug plant), USA]Sci. Cult. 45 (8), 303–307. []
  • Sharma P., Murthy P., Bharath M. S. (2012). Chemistry, metabolism, and toxicology of cannabis: Clinical implicationsIran. J. psychiatry 7, 149–156. [PMC free article] [PubMed[]
  • Sher Y., Maldonado J. R. (2015). “Major neurocognitive disorders (dementias),” in Handbook of consultation-liaison psychiatry (Cham, Switzerland: Springer; ). []
  • Showalter V. M., Compton D. R., Martin B. R., Abood M. E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligandsJ. Pharmacol. Exp. Ther. 278, 989–999. [PubMed[]
  • Silver R., Wakshalg J., Wynn S., Kramer K. (2021). “Nutritional analysis of cannabis,” in Cannabis therapy in veterinary medicine: A complete guide (Berlin: Springer Nature; ), 271–293. []
  • Silvestro S., Mammana S., Cavalli E., Bramanti P., Mazzon E. (2019). Use of cannabidiol in the treatment of epilepsy: Efficacy and security in clinical trialsJ. Mol. 24, 1459. 10.3390/molecules24081459 [PMC free article] [PubMed] [CrossRef[]
  • Singani A. A. S., Ahmadi P. (2012). Manure application and cannabis cultivation influence on speciation of lead and cadmium by selective sequential extractionSoil Sediment Contam. Int. J. 21, 305–321. 10.1080/15320383.2012.664186 [CrossRef[]
  • Sionov R. V., Steinberg D. (2022). Anti-microbial activity of phytocannabinoids and endocannabinoids in the light of their physiological and pathophysiological rolesBiomedicines 10, 631. 10.3390/biomedicines10030631 [PMC free article] [PubMed] [CrossRef[]
  • Small E. (2017). “Classification of cannabis sativa L,” in Relation to agricultural, biotechnological, medical and recreational utilization. Cannabis sativa L.-Botany and biotechnology(Ottawa, Canada: Springer; ). []
  • Small E., Cronquist A. (1976). A practical and natural taxonomy for CannabisTaxon 25, 405–435. 10.2307/1220524 [CrossRef[]
  • Small E. (2015). Evolution and classification of Cannabis sativa (marijuana, hemp) in relation to human utilizationbotanical Rev. 81, 189–294. 10.1007/s12229-015-9157-3 [CrossRef[]
  • Small E., Marcus D. (2002). Hemp: A new crop with new uses for North AmericaTrends new crops new uses 24, 284–326. []
  • Śmiarowska M., Białecka M., Machoy-Mokrzyńska A. (2022). Cannabis and cannabinoids: Pharmacology and therapeutic potentialNeurol. i Neurochir. Pol. 56, 4–13. 10.5603/PJNNS.a2022.0015 [PubMed] [CrossRef[]
  • Smith J. L., Mattick R. P., Jamadar S. D., Iredale J. M. (2014). Deficits in behavioural inhibition in substance abuse and addiction: A meta-analysisDrug alcohol dependence 145, 1–33. 10.1016/j.drugalcdep.2014.08.009 [PubMed] [CrossRef[]
  • Solinas M., Cinquina V., Parolaro D. (2015). “Cannabidiol and cancer—An overview of the preclinical data,” in Molecular considerations and evolving surgical management issues in the treatment of patients with a brain tumor (Norderstedt: Books on Demand; ), 434. []
  • Sommano S. R., Chittasupho C., Ruksiriwanich W., Jantrawut P. (2020). The cannabis terpenesMolecules 25, 5792. 10.3390/molecules25245792 [PMC free article] [PubMed] [CrossRef[]
  • Sorrentino G. (2021). Introduction to emerging industrial applications of cannabis (Cannabis sativa L)Rendiconti Lincei. Sci. Fis. Nat. 32, 233–243. 10.1007/s12210-021-00979-1 [PMC free article] [PubMed] [CrossRef[]
  • Stasiłowicz A., Tomala A., Podolak I., Cielecka-Piontek J. (2021). Cannabis sativa L. as a natural drug meeting the criteria of a multitarget approach to treatmentInt. J. Mol. Sci. 22, 778. 10.3390/ijms22020778 [PMC free article] [PubMed] [CrossRef[]
  • Stephens T. J., Mccook J. P., Herndon J. R. J. H. (2015). Pilot study of topical copper chlorophyllin complex in subjects with facial acne and large poresJ. Drugs Dermatology 14, 589–592. [PubMed[]
  • Stone J. M. (2011). Glutamatergic antipsychotic drugs: A new dawn in the treatment of schizophrenia? Ther. Adv. Psychopharmacol. 1, 5–18. 10.1177/2045125311400779 [PMC free article] [PubMed] [CrossRef[]
  • Sumner J. (2000). The natural history of medicinal plants. Portland, USA: Timber Press. []
  • Taghinasab M., Jabaji S. (2020). Cannabis microbiome and the role of endophytes in modulating the production of secondary metabolites: An overviewMicroorganisms 8, 355. 10.3390/microorganisms8030355 [PMC free article] [PubMed] [CrossRef[]
  • Taura F., Morimoto S., Shoyama Y. (1995). Cannabinerolic acid, a cannabinoid from Cannabis sativaPhytochemistry 39, 457–458. 10.1016/0031-9422(94)00887-y [CrossRef[]
  • Taura F., Morimoto S., Shoyama Y. (1996). Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L.: Biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acidJ. Biol. Chem. 271, 17411–17416. 10.1074/jbc.271.29.17411 [PubMed] [CrossRef[]
  • Taylor A. H., Amoako A. A., Bambang K., Karasu T., Gebeh A., Lam P. M., et al. (2010). Endocannabinoids and pregnancyClin. Chim. acta 411, 921–930. 10.1016/j.cca.2010.03.012 [PubMed] [CrossRef[]
  • Tetali S. D. (2019). Terpenes and isoprenoids: A wealth of compounds for global useJ. Plants 249, 1–8. 10.1007/s00425-018-3056-x [PubMed] [CrossRef[]
  • Thomas A. A., Wallner L. P., Quinn V. P., Slezak J., Van Den Eeden S. K., Chien G. W., et al. (2015). Association between cannabis use and the risk of bladder cancer: Results from the California men’s health studyJ. Urol. 85, 388–392. 10.1016/j.urology.2014.08.060 [PubMed] [CrossRef[]
  • Thomas B. F., Elsohly M. (2015). The analytical chemistry of cannabis: Quality assessment, assurance, and regulation of medicinal marijuana and cannabinoid preparations. Massachesetts, USA: Elsevier. []
  • Thomas H. (1996). A community survey of adverse effects of cannabis useDrug alcohol dependence 42, 201–207. 10.1016/s0376-8716(96)01277-x [PubMed] [CrossRef[]
  • Thomas P. A., Carter G. T., Bombardier C. H. (2021). A scoping review on the effect of cannabis on pain intensity in people with spinal cord injuryJ. spinal cord Med. 45, 656–667. 10.1080/10790268.2020.1865709 [PMC free article] [PubMed] [CrossRef[]
  • Thompson C., Sweitzer R., Gabriel M., Purcell K., Barrett R., Poppenga R. (2014). Impacts of rodenticide and insecticide toxicants from marijuana cultivation sites on Fisher survival rates in the Sierra National Forest, CaliforniaConserv. Lett. 7, 91–102. 10.1111/conl.12038 [CrossRef[]
  • Tipparat P., Natakankitkul S., Chamnivikaipong P., Chutiwat S. (2012). Characteristics of cannabinoids composition of Cannabis plants grown in Northern Thailand and its forensic applicationForensic Sci. Int. 215, 164–170. 10.1016/j.forsciint.2011.05.006 [PubMed] [CrossRef[]
  • Tipple B. J., Hambach B., Barnette J. E., Chesson L. A., Ehleringer J. R. (2016). The influences of cultivation setting on inflorescence lipid distributions, concentrations, and carbon isotope ratios of Cannabis spForensic Sci. Int. 262, 233–241. 10.1016/j.forsciint.2016.03.029 [PubMed] [CrossRef[]
  • Tireki S. (2021). A review on packed non-alcoholic beverages: Ingredients, production, trends and future opportunities for functional product developmentTrends Food Sci. Technol. 112, 442–454. 10.1016/j.tifs.2021.03.058 [CrossRef[]
  • Tomko A. M., Whynot E. G., Ellis L. D., Dupre D. J. (2020). Anti-Cancer potential of cannabinoids, terpenes, and flavonoids present in cannabisCancers (Basel) 12, 1985. 10.3390/cancers12071985 [PMC free article] [PubMed] [CrossRef[]
  • Torre L. A., Bray F., Siegel R. L., Ferlay J., Lortet‐Tieulent J., Jemal A. (2015). Global cancer statistics, 2012CA Cancer J. Clin. 65, 87–108. 10.3322/caac.21262 [PubMed] [CrossRef[]
  • Troutt W. D., Didonato M. D. (2015). Medical cannabis in Arizona: Patient characteristics, perceptions, and impressions of medical cannabis legalizationJ. Psychoact. drugs 47, 259–266. 10.1080/02791072.2015.1074766 [PubMed] [CrossRef[]
  • Turner C. E., Hadley K., Fetterman P. S. (1973). Constituents of cannabis sativa L. VI: Propyl homologs in samples of known geographical originJ. Pharm. Sci. 62, 1739–1741. 10.1002/jps.2600621045 [PubMed] [CrossRef[]
  • Tyakht A. V., Manolov A. I., Kanygina A. V., Ischenko D. S., Kovarsky B. A., Popenko A. S., et al. (2018). Genetic diversity of Escherichia coli in gut microbiota of patients with Crohn’s disease discovered using metagenomic and genomic analysesJ. BMC genomics 19, 968. 10.1186/s12864-018-5306-5 [PMC free article] [PubMed] [CrossRef[]
  • Uranga J., Vera G., Abalo R. (2018). Cannabinoid pharmacology and therapy in gut disordersBiochem. Pharmacol. 157, 134–147. 10.1016/j.bcp.2018.07.048 [PubMed] [CrossRef[]
  • Van Os J., Bak M., Hanssen M., Bijl R., De Graaf R., Verdoux H. (2002). Cannabis use and psychosis: A longitudinal population-based studyAm. J. Epidemiol. 156, 319–327. 10.1093/aje/kwf043 [PubMed] [CrossRef[]
  • Van Waes V., Beverley J. A., Siman H., Tseng K. Y., Steiner H. (2012). CB1 cannabinoid receptor expression in the striatum: Association with corticostriatal circuits and developmental regulationFront. Pharmacol. 3, 21. 10.3389/fphar.2012.00021 [PMC free article] [PubMed] [CrossRef[]
  • Van Winkel R. Genetic Risk and Outcome of Psychosis GROUP Investigators (2011). Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: Sibling analysis and proband follow-upArchives general psychiatry 68, 148–157. 10.1001/archgenpsychiatry.2010.152 [PubMed] [CrossRef[]
  • Volkow N. D., Baler R. D., Compton W. M., Weiss S. R. (2014). Adverse health effects of marijuana useN. Engl. J. Med. 370, 879–2227. 10.1056/NEJMc1407928 [PMC free article] [PubMed] [CrossRef[]
  • Wallace M. J., Wiley J. L., Martin B. R., Delorenzo R. J. (2001). Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effectsEur. J. Pharmacol. 428, 51–57. 10.1016/s0014-2999(01)01243-2 [PubMed] [CrossRef[]
  • Walters D. (2011). Plant defense: Warding off attack by pathogens, herbivores and parasitic plants. Edinburgh, UK: John Wiley and Sons. []
  • Wanmakok M., Orrapin S., Intorasoot A., Intorasoot S. (2018). Expression in Escherichia coli of novel recombinant hybrid antimicrobial peptide AL32-P113 with enhanced antimicrobial activity in vitroGene 671, 1–9. 10.1016/j.gene.2018.05.106 [PubMed] [CrossRef[]
  • Warden S. (1885). The active principle of HempInd. Med. Gaz. 19, 259–260. [PMC free article] [PubMed[]
  • Wassmann C. S., Klitgaard J. K. (2021). Combination of cannabidiol and bacitracin against bacterial infections. Odense: University of Southern Denmark. []
  • Werz O., Seegers J., Schaible A. M., Weinigel C., Barz D., Koeberle A., et al. (2014). Cannflavins from hemp sprouts, a novel cannabinoid-free hemp food product, target microsomal prostaglandin E2 synthase-1 and 5-lipoxygenasePharmaNutrition 2, 53–60. 10.1016/j.phanu.2014.05.001 [CrossRef[]
  • Wheeler M., Merten J. W., Gordon B. T., Hamadi H. (2020). CBD (cannabidiol) product attitudes, knowledge, and use among young adultsSubst. use misuse 55, 1138–1145. 10.1080/10826084.2020.1729201 [PubMed] [CrossRef[]
  • Wiles D., Shanbhag B. K., O’Brien M., Doblin M. S., Bacic A., Beddoe T. (2022). Heterologous production of Cannabis sativa-derived specialised metabolites of medicinal significance–Insights into engineering strategiesJ. Phytochemistry 203, 113380. 10.1016/j.phytochem.2022.113380 [PubMed] [CrossRef[]
  • Wilson S., Bodwitch H., Carah J., Daane K., Getz C., Grantham T., et al. (2019). First known survey of cannabis production practices in CaliforniaCalif. Agric. 73, 119–127. 10.3733/ca.2019a0015 [CrossRef[]
  • Wisniewska A., Widomska J., Subczynski W. K. (2006). Carotenoid-membrane interactions in liposomes: Effect of dipolar, monopolar, and nonpolar carotenoidsActa Biochim. Pol. 53, 475–484. 10.18388/abp.2006_3318 [PubMed] [CrossRef[]
  • Wood T. B., Spivey W. N., Easterfield T. H. (1899). III.—cannabinol. Part IJ. Chem. Soc. Trans. 75, 20–36. 10.1039/ct8997500020 [CrossRef[]
  • Xu J., Bai M., Song H., Yang L., Zhu D., Liu H. (2022). Hemp (cannabis sativa subsp. sativa) chemical composition and the application of hempseeds in food formulationsJ. Plant Foods Hum. Nutr. 77, 504–513. 10.1007/s11130-022-01013-x [PubMed] [CrossRef[]
  • Yan X., Zhou Y., Tang J., Ji M., Lou H., Fan P. (2016). Diketopiperazine indole alkaloids from hemp seedPhytochem. Lett. 18, 77–82. 10.1016/j.phytol.2016.09.001 [CrossRef[]
  • Zengin G., Menghini L., Di Sotto A., Mancinelli R., Sisto F., Carradori S., et al. (2018). Chromatographic analyses, in vitro biological activities, and cytotoxicity of cannabis sativa L. essential oil: A multidisciplinary studyMolecules 23, 3266. 10.3390/molecules23123266 [PMC free article] [PubMed] [CrossRef[]
  • Zheljazkov V. D., Sikora V., Dincheva I., Kačániová M., Astatkie T., Semerdjieva I. B., et al. (2020). Industrial, CBD, and wild hemp: How different are their essential oil profile and antimicrobial activity? Molecules 25, 4631. 10.3390/molecules25204631 [PMC free article] [PubMed] [CrossRef[]
  • Zhelyazkova M., Kirilov B., Momekov G. (2020). The pharmacological basis for application of cannabidiol in cancer chemotherapyJ. Pharm. 67, 239–252. 10.3897/pharmacia.67.e51304 [CrossRef[]
  • Zheng Z., Fiddes K., Yang L. (2021). A narrative review on environmental impacts of cannabis cultivationJ. Cannabis Res. 3, 35–10. 10.1186/s42238-021-00090-0 [PMC free article] [PubMed] [CrossRef[]
  • Ziemssen T., Thomas K. (2017). Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: An update on the clinical trial evidence and data from the real worldJ Ther. Adv. neurological Disord. 10, 343–359. 10.1177/1756285617722706 [PMC free article] [PubMed] [CrossRef[]
  • Zou J., Wang L., Tang H., Liu X., Peng F., Peng C. (2021). Ferroptosis in non-small cell lung cancer: Progression and therapeutic potential on itInt. J Mol. Sci. 22, 13335. 10.3390/ijms222413335 [PMC free article] [PubMed] [CrossRef[]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA


Leave a Reply